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ABSTRACT 
Life style disorders have been a major factor affecting all wake of the society, 
one among is Peptic ulcer disease (Eri Gunmam). Various classical medicines of 
herbal, herbo-mineral and mineral orgins were prescribed by Siddhars for tackling the 
Eri Gunmam. So I have selected Vellarugu chooranam (Gunapaadam mooligaim 
mudhal vagupu-Page.no:843) for Eri Gunmam. Eri Gunmam is a specific gastro 
intestinal disorder mentioned in the Yugi Vaidhya Chinthamani. The signs and the 
symptoms of Erigunmam more or less resemble with that of symptoms in Peptic 
Ulcer Disease (PUD) of modern medicine. This study was planned to document the 
efficacy of my trial drug in the management of Eri gunmam. 40 patients with Clinical 
Assessment Score (Grade ≥ 2) were recruited for the study and treated with Vellarugu 
chooranam (30mg/kg/bw) for 30 days. The face to face questionnaire was 
administered at the time of enrolment. The study shows the prevalence is higher in 
patients of Males (62.5%), Pitha Kaalam (34-66 yrs, 75%), Pitha Vaatha Naadi 
(57.5%) etc. After the trial, the majority of the cases showed Clinicaly Cured & well 
improvements based on clinical Assessment Score (Grade ≥ 2, 85%). The preclinical 
studies such as biochemical studies, pharmacological studies add an account for the 
anti ulcer activity. All the relevant results were statistically analysed. The study 
showed the clinical efficacy (Grade, p value<0.0001) of Vellarugu Chooranam is 
clinically significant. 
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CHAPTER - I 
INTRODUCTION 
1.1 BACKGROUND 
 
The Siddha system of medicine is one of the native systems of south India 
which was propound and practiced by well-known spiritual scientists called Siddhars. 
Siddhars were the greatest scientists of ancient times. They were men of high culture, 
intellectual and spiritual faculties combined with super natural powers.The Agasthiyar 
is considered as the father figure in siddha medical science. In siddha system, health is 
a balanced state between body and mind,  
“kdkJ nrk;ikahdhy; ke;jpuQ; nrgpf;f Ntz;lh 
kdkJ nrk;ikahdhy; thAit caHj;j Ntz;lh 
kdkJ nrk;ikahdhy; thrpia epWj;j Ntz;lh 
kdkJ nrk;ikahdhy; ke;jpuQ; nrk;ikahNk” 
kdk; J}a;ikahdhy; mJ xd;Nw NghJkhdJ. NtW vJTk; Kf;fpaky;y. 
- mfj;jpaH Qhdg;ghly;. 
 
As per siddha literature human physiology is based on 96 Thathuvas and Ezhu 
Udarkattukal which includes humours and boothas. The goal of siddha system is 
prevent ailments of body & mind, heal the sick and to provide healthy life. Prevention 
and cure are the basic aim of all systems of medicine whereas the siddha system has 
in addition the transcendental motivation. The basic emphasis of siddha system is 
based on positive health, viz, by careful dieting and proper relaxation of the mind to 
achieve a totality of health that assures not only longevity but also immortality. The 
same is expressed by Thirumoolar in Thirumathiram as, 
“kWg;g Jly; Neha; kUe;njdyhFk; 
kWg;g JsNeha; kUe;njdr; rhYk; 
kWg;g jpdp Neha; tuhjpUf;f 
kWg;gJ rhitAk; kUe;njd yhNk” 
 
In siddha system of medicine the close relation is maintained between Man 
and Prapancham (UNIVERSE). Whatever changes occurs in the prapancham 
influences the human body also. The basic elements of the universe namely, Earth 
(nilam), Water (neer), Fire (thee), Air (katru) and Ether (agayam). 
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In Tridhosa (or) three humours, when any of the thodam‟s accumulates in the 
body, the body loses its balance. The factors, which affect the equilibrium of three 
humours, are environment, climatic condition, diet and physical activities. 
According to Agathiyar vaithiya rathina surukkam the diseases were 
classified into 4448 that are commonly attacking our body. Classification was made 
on the basis of pancha bootham and tridhosa theory.In Yugi Vaithiya Chinthamani 
800, among the eight types of GUNMAM; I had selected ERIGUNMAM for this study. 
The signs and symptoms mentioned in the classical book closely resembles with that 
of Peptic Ulcer Disease in modern medicine. So, I had selected the medicine 
VELLARUGU CHOORANAM  for the management of  ERIGUNMAM. 
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1.2 AIM AND OBJECTIVE 
 
1.2.1 AIM  
To evaluate the clinical efficacy of Siddha medicine Vellarugu Chooranam 
(Internal medicine) in the management of  Eri Gunman (Peptic ulcer disease). 
 
1.2.2 PRIMARY OBJECTIVE 
To document the therapeutic efficacy of Vellarugu Chooranam (Internal 
medicine) in the treatment of  Eri Gunmam (Peptic ulcer disease). 
 
1.2.3 SECONDARY OBJECTIVE 
1. To study about the 
i. Siddha diagnostic parameters 
ii. Habits of voluntary control of Reflexes(14 vegangal), Udarthee, Thegi 
Ilakkanam, Gunam, Manikadainool in Erigunmam 
iii. To evaluate the clinical symptoms before and after treatment to rule 
out the efficacy of Vellarugu Chooranam  
2. To study about the 
i. Uyirthathukkal properties in Eri Gunman 
3. To evaluate the  
i. Biochemical, 
ii. Phyto-chemical, 
iii. Anti-Microbial  
4. To screen the Pharmacological activities of Vellarugu Chooranam. 
5. To evaluate the acute and sub acute toxicity of Vellarugu Chooranam. 
6. To do Difference analysis with SPSS for, 
i. Evaluating the clinical efficacy of Vellarugu Chooranam using clinical 
assessment score. 
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CHAPTER - II 
REVIEW OF LITERATURE 
2.1 GUNAPADAM ASPECT   
VELLARUGU 
  
 
 
 
 
 
 
 
 
 
 
 
BOTANICAL NAME : Enicostemma axillare lam 
NAMES   
Tamil                    : Vellarugu, Vallari 
English                 : Indian white head 
Hindi                    : Chota chirayata 
Telugu                    : Chevvu kurti 
Bengali   : Nagajiva 
Gujarathi    : Mamijiva 
Malayalam            : Vellaruku, Vallari 
Marathi    : Kadavinayi 
PART USED    : whole plant 
 
PROPERTIES   
Suvai (Taste)       : Kaippu 
Thanmai               : (Nature) Veppam 
Pirivu (Bio- Transformation) :  Kaarppu  
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ACTIONS 
1. Stomachic 
2. Tonic  
3. Laxative 
4. Alternative 
5. Febrifuge 
 
2.1.1 Ingredients and Medicinal uses of Vellarugu Chooranam 
TAMIL 
NAME 
PHARMACOLOGICAL 
ACTIONS 
THERAPEUTIC USES IN 
SIDDHA 
Vellarugu 
Anti-ulcer, Anti-spasmodic, 
anti-inflammatory, Anti 
microbial, Anti oxidant, 
Analgesic. 
Gunmam, Vali Noi, Kudal vadham, 
Soolai, Ulluru Kiranthi, Dhinavu, 
Sirangu. 
(Gunapadam Mooligai Muthal PagamPage No.843) 
Synonyms             : Enicostemma littorale blume 
   : Enicostemma hyssopifolium verdon 
2.2 IN JOURNAL 
Taxonomy 
 Kingdom  : Plantae 
 Subdivision : Angiospermae 
 Class  : Dicotyledonae  
 Subclass  : Gamapetalae  
 Series  : Bicarpellatae  
 Order  : Gentianales 
 Family  : Gentianacae  
 Genus  : Enicostemma 
 Species  : axillare 
Geographical distribution 
  This tropical genus is widely distributed in India, South America, Africa, and 
Asia. E. axillare grows in many diverse habitats from savannas, grasslands, forests to 
beaches, from wet to very dry and also survives in a very saline environment 
(Rajamani et. Al 2013).  
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Morphology  
 Enicostemma axillare is an erect, perennial herb, 5-30 cm tall, simple or 
branched at the base. Stem is cylindrical, glabrous with a decurrently ridge below 
each leaf. Leaves are sessile sometimes narrowed into a petiole-like base, longer than 
the internodes; lamina (5.0-8.0-0.3-1.0) cm, linear to lanceolate or narrowly oblong, 
entire, obtuse and marinate at the apex, somewhat narrowing towards the base, 3-
nerved from the base, glabrous. Inflorescence in many flowered auxiliary clusters, 
numerous in the axils of each pair of leaves. Flowers are white with green lines, 
drying yellowish, sessile or sub sessile; bracts long, shorter than the calyx, lanceolate-
acuminate, carinate. Calyx tube 1-2 mm long; lobes usually unequal, (0.7-1.5- 0.4-
0.7) mm, triangular to lanceolate, acute at the apex and narrowly scarious at the 
margin, or obviate to sub circular, obtuse and marinate at the apex, with wide scarious 
margin. Corolla tube is 3.5-6.0 mm long; lobes (1.5-2.0-0.7-1.0) mm, ovate and 
abruptly narrowing to an acute or mucronate apex. Stamens inserted below the 
sinuses, just above the middle of the tube; filaments 1.5-2.3 mm long, with a double 
hood at the insertion point (Rajamani et. Al 2013). 
 
Chemical compounds 
This plant comprises of different chemical compounds. Many compounds 
have been isolated from the plant, E. littorale. Tanna et al. reported that the aerial part 
of the plant gave 34% of dry alcoholic extract and 15.7% of ash. The presence of 
minerals like iron, potassium, sodium, calcium, magnesium, silica, phosphate, 
chloride, sulphate and carbonate were estimated in the qualitative analysis of ash. 
Natarajan and Prasad reported the presence of five alkaloids, two sterols and volatile 
oil. Betulin, a triterpene sapogenin was also isolated by earlier workers. Monoterpene 
alkaloids like enicoflavin, gentiocrucine and seven different flavonoids were isolated 
from the alcoholic extract and the structures were identified as apigenin, genkwanin, 
isovitexin, swertisin, saponarin, 5-o glucosylswertisin and 5-o glucosylisoswertisin 
were also isolated by Goshal et al. The presence of catechins, saponins, steroids, 
sapogenin, triterpenoids, flavonoids and xanthenes and new flavones C-glycoside 
named as Verticilliside was isolated for the first time this species was reported by 
Jahan et al. Swertiamarin compound was isolated from E. littorale by using alcoholic 
extract. Six phenolic acids like vanillic acid, syringic acid, p-hydroxy benzoic acid, 
protocatechuic acid, p-coumaric acid and ferulic acid were also found by Desai et al. 
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Methanol extract of E. littorale was found to be containing different amino acids like 
L-glutamic acid, tryptophan, alanine, serine, aspartic acid, L-proline, L-tyrosine, 
threonine, phenyl alanine, L-histidine monohydrochloride, methionine, iso leucine, L-
arginine monohydrochloride, DOPA, L-Glycine, 2-amino butyric acid and valine. 
Swertiamarin is a representative constituent of many crude drugs, which are marketed 
in Japan and other countries and these crude drugs are normally evaluated by their 
high swertiamarin content (Rajamani et. Al 2013). 
 
2.2.1 Phamacological Screening  
Antiulcer and anti-inflammatory activity    
Roy et al. 2010 study showed the aerial parts of E. littorale against aspirin, 
ethanol and pyloric ligation induced ulcers in rats and bovine serum albumin (BSA) 
denaturation were examined for antiulcer and anti-inflammatory effects. The extract 
was administered to the overnight fasted rats, one hour prior to aspirin or alcohol or 
pyloric ligation challenge. The ulcer index, tissue GSH levels and lipid peroxidation 
levels in all the models of ulcers and the volume of gastric secretion, acidity and pH 
were estimated in the pyloric ligation model of ulcers. Pre-treatment with the aqueous 
extract of E. littorale showed a dose-dependent decrease in the ulcer index against 
aspirin, ethanol challenge and pyloric ligation. The prior administration of the 
aqueous extract also reduces the total acidity, free acidity, volume of gastric secretion 
and elevated the gastric pH. In addition, it was also observed that the aqueous extract 
inhibits the serum albumin denaturation in a dose-dependent manner. It was reported 
that the methanolic extract of E. littorale possesses antiulcer activity. And its anti-
inflammatory activity may be attributed 
 
Anti-Oxidant Activity 
A.Krishnaveni et al.2012 has studied & observed the following, Three 
successive extracts of the whole plant of Enicostemm aaxillare (E.axillare) were 
examined for in vitro Anti oxidant activity using eight different methods. All the three 
extracts have shown a significant and potent result than the standard one. Ethanolic 
extract showed higher values in ABTS+, DPPH, FRAP, SOS and NOS Radical 
Scavenging activity.Methanolic extract has shown higher values in TRAP assay. 
Petroleum ether extract also has shown a significant result i.e., higher than the 
standard but lesser than the other two extracts. All the three extracts have shown 
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higher values in total phenol and flavanol content. Hence, this project paves the way 
to study the anti cancer, anti inflammatory and anti diabetic activities of Enicostemma 
axillare. 
 
Anti-Inflammatory activity 
G. Leelaprakash et al.2011 has done methanol extracts of Enicostemma 
axillare and found that it possess Anti-inflammatory properties. These activities may 
be due to the strong occurrence of polyphenolic compounds such as alkaloids, 
flavonoids, tannins, steroids, and phenols, The extract fractions serve as free radical 
inhibitors or scavenger or acting possibly as primary oxidants and inhibited the heat 
induced  albumin denaturation, proteinase activity and stabilized the Red Blood Cells 
membrane. EAME also reduced the activity of lipoxygenase. Purification of each 
bioactive compound is necessary and this purified form of the compound can be used 
which may show increased activity. This study gives on idea that the compound of the 
plant Enicostemm aaxillare can be used as lead compound for designing a potent anti-
inflammatory drug which can be used for treatment of various diseases such as 
cancer, neurological disorder, aging and inflammation.  
 
Hypocholestrolemic and Antioxidant activity: 
Vaijanathappa J et al .2001 studies show that, the plant consists of flavonoids 
and phenol compounds which exertcardiovascular benefits. The 85% Methanolic 
extract of plant Enicostemmaaxillare showed hypocholestrolemic effect in fructose 
induced hyperlipidemicanimals. The dose of Enicostemma axillare (150mg/kg) 
decreased thelevel of cholesterol, Triglycerides, LDL and VLDL and increased 
HDL level. The extract might be inhibitors of HMG CO A reductase by 3 fold.Due 
to rich source of vitamin C, vitamin E and tannins inhibits the formation of OX-
LDL.Hence this extract displays antioxidant activity by increasing activity of 
enzymatic antioxidant like GPX and catalase and nonenzymatic antioxidant like GSH. 
Hence Enicostemma axillare is rich source of phytoconstituent which are used as 
potent hypocholestrolemic and antioxidant agent in pharmaceutical industry. 
 
Antimicrobial and Antioxidant activity: 
Sharada Deore L  et.al 2008 has determined the Invitro antimicrobial activity 
(well diffusion method) of aqueous, hydroalcoholic, Methanolic, chloroform and ethyl 
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acetate extracts of leaves of Enicostemma axillare plant has been evaluated by using 
six bacterial species and some fungi such as Staphylococcus aureus, Bacillus 
subtillis,Proteus vulgaris, Escherichia coli, Pseudomonas aerogenosa, Shigella 
sonni,Aspergillus niger and Candida albicans observed that chloroform, ethyl 
acetate and hydroalcoholic extract showed prominent antimicrobial activity with 
highest zone of inhibition against all microorganisms. Invitro antioxidant activity of 
each extract except ethyl acetate by Nitric oxide and DPPH method shows antioxidant 
activity following sequence: Methanol > Hydroalcohol > Aqueous > Chloroform. 
 
Anti oxidant and Hepatoprotective Activity: 
Jaishree et.al 2010 observed that, Swertiamarin isolated from Enicostemma 
axillare of successive ethyl acetate extract showed antioxidant and Hepatoprotective 
effect against Dgalactosamine induced acute liver damage in rats. The dose of 
Swertiamarin (100-200mg/kg BW) interaperitonially against D-galactosamine which 
induced liver injury is used. The dose caused significant restoration of all the altered 
biochemical parameters i.e. elevation of antioxidant enzymes catalase, superoxide 
dismutase and glutathione and decreased level of MDA in serum liver and kidney to 
become normal. The potent dose 100 and 200 mg/kg for 8 days showed 
Hepatoprotective activity due to Invitro antioxidant property. 
 
Anti edematogenic and Free Radical Scavenging Activity: 
Vaijanathappa et.al2009 study showed that Swertiamarin from ethyl acetate 
extract shows antiedematogenic activity using Carrageenan-formalin and Histamine–
induced Paw edema methods in rats. In this method, edema inhibition obtained after 
5hr. Induction were 38.60%, 52.50% and 45.44% for 100mg/kg, 200mg/kg BW 
Swertiamarin. The 100mg/kg Diclofenac sodium used as standard. It also shows 
Invitro antioxidant activity using seven different methods. Out of which good activity 
observed in ABTS (2.83 μg/ml, IC50). Hydrogen peroxide methods (5.70 μg/ml, 
IC50) moderate activity in hydroxyl radical by deoxyribose (52.56 μg/ml, IC50) and 
lipid peroxidation methods (78.33 μg/ml, IC50). Hence total antioxidant capacity was 
found to be 4.51mM of ascorbic acid per gram of Swertiamarin. 
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In vitro anti-inflammatory activity. 
G. Leelaprakash et.al 2011study showed that, Methanolic extract (ME) of 
whole plant Enicostemma axillare (EA) was evaluated for anti-inflammatory activity 
by albumin denaturation assay; proteinase inhibitory activity at different 
concentrations .Aspirin, Diclofenac and Indomethacin were used as standard drugs. 
The result shows EA ME at conc. range of 100-500 μg/ml significantly (p<0.01) 
protects the heat induced protein denaturation. At the concentration 400 and 500 
μg/ml EA ME showed significant (p<0.01) inhibition of 42 and 53% of proteinase 
inhibitory action. At the concentration of 100 and 200 μg/ml did not show significant 
(p>0.05) activity. Heat induced haemolysis of erythrocyte was significantly (p<0.05) 
inhibited at conc.400 and 500 μg/ml. hypotonicity induced haemolysis and 
lipooxygenase activity were significantly (p<0.01) inhibited at concentration range 
200,500 μg/ml and 400,500 μg/ml respectively. It  is indicated Methanolic extract of 
Enicostemma axillare can be potential  source of anti-inflammatory agent. 
 
Antinociceptive activity  
According Jaishree etal2009, Swertiamarin is used to relive pain. Three 
different methods in mice, for invivo antinociceptive activity were carried. In the hot 
plate method a significant increase in latency period was observed at 100mg/kg and 
200mg/kg/BW of Swertiamarin after 30 and 45 min.The percent protection observed 
after 45 min. was 109.42 (100mg/kg bw) 147.42(200mg/kg bw) and 157.14(standard 
Paracetamol). In second method increases in the tail withdrawal reflex was observed 
in which Swertiamarin give percent protection 150(100mg/kg) and 200 (200mg/kg). 
In third method, acetic acid induced writhing Swertiamarin at 200mg/kg BW showed 
potent and both peripheral and central antinociceptive activity than that of 
Paracetamol. 
 
Anti epileptic activity 
  Shalini et.al 2012 study showed that, The aqueous and chloroform extract of 
Enicostemma axillare were nontoxic up to recommended dose 2000mg/kg body 
weight orally as per OECD guidelines. The antiepileptic activity by maxima 
electroshock (MES) and pentylenetetrazole (PTZ) induced seizures in albino wistar 
rats shows onset of myoclonic spasm and clonic convulsion were delayed in test 
groupof dose 200 and 400 mg/kg bw of aqueous and chloroform extract. 
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Anticonvulsant activity observed against MES and PTZ animal models. The percent 
protection of chloroform extract 200mg and 400mg dose in MES 82.43%, 83.04%. 
Respectively in PTZ induced convulsion 200mg and 400mg85.52%,82.67% resp. 
which is better than Hydroalcoholic extract in MES induced 200mg(2.75% ) and 
400mg (70.93%) and PTZ induced 200mg (70.02%) and 400mg (71.58%) dose. 
 
Antibacterial activity 
Pavithraet.al 2010 study showed that, the organic solvent extract of 
enicostemma axillare by disk diffusion and broth dilution technique shows 
antibacterial activity against gram positive bacterial strains. Results revealed that 
methanol extract of enicostemma axillare showed activity against B.subtilis and were 
not bactericidal at 100mg/ml (MBC).  
 
2.3 SIDDHA ASPECTS  
2.3.1 Introduction 
                        “mz;lj;jp Ys;sNj gpz;lk; 
gpz;lj;jp Ys;sNj mz;lk; 
mz;lKk; gpz;lKk; xd;Nw 
mwpe;Jjhd; ghh;f;Fk; NghNj” 
-rpj;j kUj;Jthq;fr;RUf;fk; 
 
According to the siddha system, “Whatever seen in macrocosm, is to be 
present in the microcosm. Living & Non-living things in the world consists of five 
elements namely.Man, Neer, Thee, Vayu andAkayam.These five elements are the 
basics of the three humours namely Vatham (creative function), Pitham (protective 
function) and Kabam (destructive function) 
 
thjkha; gilj;J gpj;j td;dpaha; fhj;J Nrl;k rPjkha; Jilj;J” 
        -NjuH Nrfug;gh 
mwpT tbT vd;wwpahj vd;id 
mwpT tbT vd;wUs; nra;jhd; ee;jp 
mwpT tbT vd;wU shywpe;Nj 
mwpT tbT vd;wwpe;jpUe; NjNd. 
      -jpU%yu; 
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 From time immemorial, people tried their best to realize oneself (mwpT-
Md;kh) & get free from karma. Some of them realized, and came to known as 
Siddhars (Siddh-static). During their achievement, they came across many obstacles 
such as environmental factor, ageing factor, diseases, death etc. To overcome these 
obstacles, they do research elaborately. 
 Their research results evolves as „Siddha’system with the unique features of a 
developed life style, which deals with morality of day [naal ozhukkam ] and seasons 
[kaala ozhukkam]; Yogam[astanga yogam]; Kayakarpam [pothu karpam & sirappu 
karpam]; Astrology; Diseases under topics of aetiology , classification, 
treatment[medicine & surgery], preventive measures etc. 
  
“kpfpDk; FiwapDk; Neha;nra;Ak; EhNyhh; 
; tspKjyh vz;zpa %d;W” 
    - jpUf;Fws; 
The ratio between these three humours is 1, 1/2, 1/4. Any imbalances can 
result in diseases. Diseases of GIT (Gastro intestinal tract) and related organs are 
described under the entity GUNMAM in our texts. 
 
2.3.2 Definition- GUNMAM 
Gunman is a gastro intestinal disorder characterized by gradual deterioration 
of physico-psychological health eventually leading to fatality. In this disease, patient 
feel food pain pattern leading to burning sensation, which is relieved by vomiting. A 
repetitive episode leads to malnourishment of the subject.In another concept; 
Gunmam can be explained as accumulation of vayu leading to rumbling beat in 
stomach causing severe discomfort of the stomach.  
 
2.3.3 Etiology 
 Diseases are due to alteration in diet & activities. 
“czthjpnray;fshy; Neha; nra;Ak;” 
  -nghJ kUj;Jtk; 
 
1. Causes due to changes in activities 
2. Causes due to altered food  
3. Infective causes 
4. Astrological causes 
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2.3.3.1 Causes due to changes in activities:- 
1. Controlling the reflexes such as, 
 Abanavayu 
 Appetite 
 Thirst 
 Tears 
 Yawning 
 Fatigue 
2. Excessive boredom, Resentment, sexual desire. 
3. Abusing an expert (master), God, Father, mother, child, opposite sex. 
4.  Fate due to cruelty such as humiliating others etc. 
 
(1)“thjj;ij jil nra;jhNyh  
    khu;GNeha; Fd;k thA” 
   “tpopapdpy; ePulf;fpy;…. 
    …..thjq; $by;…… 
    …….Fd;kk; gw;wpLq;….” 
    “Ngrpa fisg;g lf;fpy; 
    …..Fd;kk;” 
       -rpj;j kUj;Jthq;f RUf;fk; 
 
(2)“ikahd kq;ifAld; khh;f;fj;jhYk;……. 
ijahs rz;lhs Nfhgj;jhYk;  
rypg;ghYk; Fd;kk; te;J jhf;Fk; ghNu” 
–a+fp itj;jpa rpe;jhkzp 
 
(3)“ghh;f;fNt FUepe;ij gz;zpNdhh;f;Fk;  
ghy;fiu rpRit gl;bdpitj; Njhh;f;Fk;  
khh;fkhk; khjhit gpjhit epe;ij  
tQ;rid jhd; nra;Njhh;f;Fk; kle;ijjid  
fhh;f;fNt fw;gopj;j fhKfh;f;Fk;  
fUjpNa rptepe;ij gz;zpNdhh;f;Fk;  
Mh;f;fN al;lFd;kk; kDF nkd;W  
mwd; nrhy;y Njtpnrhd;dhswpe;J ghNu” 
     –a+fp itj;jpa rpe;jhkzp 
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 (4)  “Fd;kk; te;j fhuze;jh NdNjhntdpy; 
FbnfLj;J tapw;nwhpr;ry; nfhz;l ghtk; 
ed;ikapy;yh kdf;ftL ngUj;j ghtk; 
ey;Nyhiu kdk; Nehf gopj;j ghtk; 
jd;ikapy;yh gpwh; grpf;f cz;l ghtk; 
rz;lhs jj;JtNk nra;j ghtk; 
,k;ikapy; ,g;ghtk; te;J Rw;wp 
mjdhNy Fd;knkd nTFj;j thNw” 
–mfj;jpah; fd;k fhz;lk; 
 
2.3.3.2 Causes due to altered food  
1. Excessive intake of astringents, tubers, Pepper. 
2.  Intake of hot water before food. 
3.  Food adultered with fine stones, paddy, hair. 
     
  (1)“nra;ahd Fd;kj;jpDw; gj;jp jd;idr;  
nrg;gplNt Jth;g;ghd Grpg;gpdhYk;…… 
… ca;ahd kpsFtif Aiug;gpdhYk;….. 
…..tifahf fpoq;Ftif apUe;jhYk;” 
       –a+fp itj;jpa rpe;jhkzp 
 
(2)CDf;F Kd; ePUz;lhw; grpg;Nghk;  
tPDf;F Fd;kk; tpisAk; fhz” 
–gjhh;j;jFzrpe;jhkzp 
 
(3)“Rakhd FlypYs;Ns fy;Ykp ney;YkhNk  
fy;NyhL kapuhAs;s frlJ Flypw; gw;wp 
    –guuhrNrfuk; 
2.3.3.3 Infective causes 
  Due to microorganisms, 
 
 ty;Ygha; fJtha; md;dk; nrhpahj khrpdhNy  
nky;ypa fpUkp nfhz;L Fd;k Neha; kUTq;fhNd” 
–guuhrNrfuk;  
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2.3.3.4 Astrological causes 
 In Horoscope,   
 The lord of 5th place is in weak stage(Neesam,  Pagai, kiragayuththam, 
in 6
th
 ,8
th
 ,12
th
 place), 
 The most perishing Graham in Laknam (1st place), 
 Sani Graham in 7th place. 
 
  “nrhy;ypa Ie;jpDf;F ,iwth; Jh;gyNk Mfpjp  
nrhy;Y kjpghyh; tjak; nrd;wpUf;f MSikNahd;  
ty;YWNt Nuk; ghh;f;f td;rd; Voptpy; epw;f  
nfhy;Yk; ekidg; Nghyhff; Fd;kk; Nuhfe; Njhd;Wk;” 
–kzpke;jpu itj;jpa Nuhfk;  
 
2.3.4 Classification 
Few more school of thoughts also explains classification of Gunmam: 
 
S.no/ 
Author 
Yugi Muniver 
Thirukanda 
Munivar 
Thirumoolar Vada nool 
 
1.  Vayu Gunmam 
or Payuru 
Gunmam 
Vadha Gunmam Vadha 
Gunmam 
Vadha 
Gunmam 
 
2.  Vatha Gunmam Pitha Gunmam PithaGunmam PithaGunmam  
3.  Pitha Gunmam KaphaGunmam Iya Gunmam Iya Gunman  
4.  Sethma 
Gunmam 
Vatha Pitha 
Gunmam 
MegaGunmam Vatha Pitha 
Gunman 
 
5.  Eri Gunmam Vatha Kapha 
Gunmam 
 Vatha Kapha 
Gunman 
 
6.  Vali Gunmam Pitha Kapha 
Gunmam 
 Pitha Kapha 
Gunman 
 
7.  Sathi Gunmam Thrithoda 
Gunmam 
 Sanni Gunmam  
8.  Sanni Gunmam Raththa 
Gunmam 
 Raththa 
Gunmam 
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            “nra;aNt vz;Fd;k nraiyf; Nfsha;  
nrayhd thA Fd;kk; thj Fd;kk;  
va;aNt gpj;j Fd;kk; vhpFd;kkh Fk;  
Vyhd typFd;k rj;jp Fd;k  
ijaNt rd;dp Fd;kQ; Nrl;g Fd;k  
rhfrkhq; Fd;k nkl;L khFk;  
nfha;aNt apjDila Fzq;fnsy;yhk;  
Fwpg;gwpe;J xt;nthd;wha;$h;e;J ghNu” 
-a+fp itj;jpa rpe;jhkzp 
“vd;wjpy; thjFd;k typFd;kk; rf;jp Fd;kk;  
Jd;wpa #yFd;kk; nrhy;Ykp jrhj;jpae;jhd;  
 
fd;wpa gpj;jFd;kq; fgFd;kq; Fd;k#iu  
nahd;nwwp Fd;kk; ehd;F Kz;ikaha; jPUq;fhNd” 
- jd;te;jphp itj;jpak; 
 
“jhdhd Fd;ktif vl;Lkpe;jj;  
 juzpap Yz;lhd tpjj;ijf; Nfsha;   
  ………………………………….” 
- mfj;jpah; Fzthflk; 
 
“ky;yhUk; ml;l Fd;kk; ….” 
- gjhh;j;j Fz rpe;jhkzp 
 
“nrg;gpNdhq; Fdk; nkl;Le; njdpNt khdplh;f;F 
  xg;gpyh gy E}yha;e;J xOq;Fld; gpzpfs; ePq;f” 
- Mj;k uf;\hkph;jk; 
 
“gz;zpa thjgpj;jk; gfiua Fd;kNkhL 
rd;dpNa nahpT Fd;kk; fdj;Jly; gpul;Lq; Fd;kk; 
ed;dpNa rj;jp Fd;kk; ehbLQ; #iy Fd;kk;  
Fd;dpNa typj;j Fd;kk; Fjpj;Njhl …” 
- mf];jpah; kzf;Nfhyk; 
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2.3.5 Pathogenesis 
 
“njhlu;thj ge;j kyhJ Fd;kk; tuhJ” 
-Njud;  
 
As per the aetiological aspects collected from various siddha literatures we 
conclude to know food habits and immoral behaviouralchanges can lead to increase of 
vatha humour in the pithasthanam namely stomach (mfL). Hence the equilibrium 
maintained among the three humours (Vatha, Pitha, and Kaba) was disturbed. 
 
 
  
 
     Which inturn causes 
  
  
 
 
  
 
 
 
  
  
 
In the pathogenesis of Eri Gunmam, the changes in three humours play major 
role in the development of diseases which causes changes inudal thathukkal affects 
the udal vanmai and these pathological changescan be seen by the eight types of 
examination that is Envagai thervugal. 
 
“gpj;jNk fjpj;jNghJ ngUj;jpLk; thjKz;lhk; 
gpj;jNk fjpj;jNghJ ngUj;jpLk; tapw;wpy;thA 
gpj;jNk fjpj;jNghJ ngUj;jpLk; gpj;NjNfS 
gpj;jNk fjpj;jNghJ ngUj;jpLk; gpzpaNefk;” 
 - Nuhf epjhd tpyk;gfk; mfj;jpadhu; 
Derangement of Vatham 
Altered function of 
Abanavayu &Uthanavayu 
 
 
 
 
 
Derangement in Pitham and 
Kabam 
Indigestion 
Symptoms of Gunmam 
Altered diet & life style 
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“$wplNt gpj;jkJ rPwpw;whdhw; 
nfhLq;fhe;j Yly;twl;rp eLf;FKz;lhk; 
kPwplNt tNuhrpae;jh dhtwl;rp 
Nkyhd NrhgkJ tpf;fy;%u;r;ir 
J}wplNt fpWfpWg;Gf; fhjilg;Gj; 
njhe;jkhq; frg;GlNd kz;ilf;Fj;J 
khwplNt neQ;nrupT mf;fpke;jk; 
kfj;jhd Fspu;RuKq; fha;jyhNk.” 
 
“MNkjhd; m];jpRuk; ghz;L Nrhif 
moyhd tplhr;RuKk; gpuNkfe;jhd; 
NghNkjhd; fhkhiy gpj;j ntl;il 
nghy;yhj ghz;LlNd rpte;j ePuhk; 
NjNkjhd; rptg;ghA kQ;rshAk; 
rpWrpWj; jpUz;LtUq; FoptpOe;J 
ehNkjhd; nrhd;NdhNk gpj;jf;$W 
etpd;wpl;lhu; thrKdp etpd;wpl;lhNu” 
- rpfpr;rh uj;d jPgk; 
 
“gFj;jpbw; gpj;jk; gygy rpe;ijahk; 
tFj;jpLk; the;jpAk; tha;ePu; kpfT+Wk; 
kFj;jpL Nkdpapy; khl;b naupg;NgWk; 
kpFj;j tdpf;F kpftplq; iff;FNk” 
- jpU%yehadhu;  
   
“jhdhd Fd;k tif vl;L kpe;j  
   juzpapYz;lhd tpjj;ijf; Nfsha;  
  Czhd mrPuzj; jhype;j Nuhfk;  
   cw;gj;jpahF nkd;Nw cWjp nrhy;Y” 
- mfj;jpah; Fzthflk; 
 
“Vw;wpa Fd;K nkOe;j tpjq;Nfs; 
Njhw;wpa gpj;jKk; thATk; njhe;jpf;fpy; 
Nrw;wp td;dk; nrhpf;fpy; typg;NgWk; 
khw;wpa ePUjp the;jpAkhNk” 
–jp&%yh; fUf;fil itj;jpak; 
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2.3.6. Symptoms of Eri Gunmam 
 
„jpLf;Fkh nkhpFd;kr; nraiyf; Nfsha;   
   rpWtapw;wp nyhpe;JNk Fly; FKWk;   
  tLf;Fk;tha; ePh;Ruf;Fk; jiytypf;Fk;  
   tapWg;gpf; fpWfpWf; Fk; gpspe;Njf;fhFk; 
  ntbf;Fkapu;f; fhy;NjhWk; tpah;it ahFk;  
   kpfg; nghUkp tapWfope; jpiur;ryhFk;  
  vLf;FNk Alypisf;F kpuq;fh jd;dk;  
   vhpANk Alnyq;F kpUk yhNk.” 
       -a+fp itj;jpa rpe;jhkzp 
 
  Nktpa Fd;ke;jhd;ndOe;jNjhh; tpjq;fs; nrhy;Nthk; 
ghhpa gpj;jj; njhLk; thjKk; ghpe;J Nrhpy; 
Thfpa tz;z ePUk; the;jpakhFk; ghNw 
ghug;gh thA thjk; ghpTlNd ghtd;wq;fpy; 
Vug;gh ehb jd;id tuz;Ljhd; kpfNt NehFk; 
Nfhug;gh neQ;rpw; Fj;Jk; Fliy KWf;fpf; nfhz;L 
thug;gh typf;F nkj;j thjkha; toq;Fk; tha;Nt 
toq;fpa mg;GNthL thj nkd;Nwahy; 
Koq;fpa KWf;FNkdp jpiuAk; tijf;Fq;fhNy” 
- mf];jpah; itj;jpa fhtpak;. 
 
 
Descriptive features of Eri Gunmam among different literatures: 
 Burning Pain 
 Nausea 
 Water brash 
 Headache 
 Flatulence 
 Regurgitation 
 Lack of food intake 
 Dizziness 
 Sweating 
 Loss of body weight 
 Neuritic pain 
 Cough 
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  “tapw;iw nahpf;Fq; Fly; Gul;b tha;ePh; Row;wpj;jiyfdkh 
Kaph;g;ig aopf;ff; fpWfpWf;F Nkhq;fhhpf;F Nkg;gKz;lh 
kaph;f;fhy; topNa tpah;tUk;gp tapW nghUkp afd; wpLfp 
ypaw;wp nahpf;Fq; Fd;knkd apikNahh; nrhd;d KiwahNk”. 
- jd;te;jhp itj;jpak; 
-  
“tapw;iw nahpj;jpl;Lf;Fly;tha;ePh;Row;wp j;jiyfdj;J 
caph;g;igawpaf ;fpWfpWf;F Nkhf;fhspj;J Ntg;gKz;lh 
kaph;f;fhy sNtNth;it tUk;tapWnghUkp afd;wpLjy; 
ypaw;Wl ndy;yhnkhpf;F nkhpFd;kj;jpd; FzkpJNt.” 
- MAs; Ntjk; 1200 
-  
Erigunmam in Vaidhya Sara Sangraham  
 tapW vg;NghJk; ,iuAk; 
 tapW nghUKk; 
 Fliyg; Gul;b xf;fhspf;Fk; 
 Vg;gkpLk; 
 jiyfdj;J typf;Fk;> fpWfpWf;Fk; 
 kapu;f;fhy; top tpah;f;Fk; 
 
Erigunmam in Sikicharathna Deepam  
 tapw;wpy; vhpr;ry;> tapw;Wg;gprk;> tapw;wpiur;ry; 
 Fly; Gul;ly; 
 tha;ePUjy;> tha;Fkl;ly; 
 GspNag;gk; 
 rhPuk; ,isj;jy;> vhpr;ry; 
 md;dk; nry;yhik 
 ,Uky; 
 
Erigunmam in Seevarakchamirtham 
 mbtapw;wpy; vhpr;ry; 
 Fly;Fkl;ly; 
 tha;ePUwy; 
 jiyRoyy; 
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 tapWg;gy;> ,iur;ry; 
 GspNag;gk; 
 Nuhkj;Jisfspy; tpah;it ngUfy; 
 Ngjp 
 rhPuk; ,isj;jy; 
 md;dk; nry;yhik 
 ,Uky;. 
 
The symptoms of Eri gunmam are also discussed in Anubava Vaidhya 
Devaragasiyam and Sarabendrar Gunma Roga Sikitchai text book. 
 
Table 2.3.6 Symptomatology [Yugi] 
 
Sl. 
No 
Type of 
Gunmam 
GIT 
 
CNS CVS RS Others 
1. 
 
 
Vatha 
Gunmam 
Constipation, 
Loss of 
appetite, 
Dryness of the 
tongue 
 
Sleepiness, 
Giddiness, 
Difficulty in 
walking, 
Paraesthesia, 
Headache, 
Burning 
sensation, 
- - Pain all over 
the body, 
Restriction 
of walking, 
Heaviness of 
the body. 
 
2. Pitha 
Gunmam 
Vomitting, 
Excessive 
thirst, 
Constipation 
Paraesthesia, 
Giddiness 
 
- Cough, 
Breath 
lessness 
 
Yellowish 
discolouration 
of the face, 
Fever, 
Burning 
Micturition 
3. Silethuma 
Gunmam 
 
Ptylism, Loss 
of appetite 
 
Haeviness of 
the head 
 
Gross 
pallor 
 
Dry 
cough 
 
Emaciation, 
Fatiguability, 
Rigor, 
Stupor 
4. Sanni 
Gunmam 
Loss of 
appetite, 
Giddiness,unco
nsciousness 
- Dry 
cough, 
Rigor, 
Chillness 
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Borborygmus, 
Ptylism, 
Diarrhoea, 
Burning 
sensation in 
the 
stomach, 
Salty 
taste in the 
tongue 
 
 
Breath 
lessness 
 
5. Eri 
Gunmam 
 
Burning 
sensation in 
the 
Stomach, 
Ptylism, 
Flatutance, 
Belching, 
Diarrhoea, 
Nausea. 
Headache, 
Giddiness, 
Perspiration 
 
- cough Emaciation, 
Burning 
sensation all 
over the 
body 
6. Vayu 
Gunmam 
 
 
 
Indigestion, 
Loss of 
appetite, 
Flatulence, 
Pain in lower 
Abdomen 
Paraesthesia - - Fatiguability, 
dryness of 
the body, 
Restriction 
of walking 
7. Saththi 
Gunmam 
 
- 
 
Burning 
sensation in 
the 
upper 
abdomen, 
Constipation, 
Loss of taste, 
Increased 
Appetite 
 
 
Giddiness, 
Unconscious 
ness 
 
- Cough Fatiguability, 
Varicosity, 
Burning 
sensation, 
Restriction 
of walking 
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8. Vali 
Gunmam 
 
 
 
 
 
Flatulance, 
Borborygmus, 
Loss of 
appetite, 
Hypochondric 
pain radiating 
to back, False 
Appetite. 
Disturbed 
sleep, 
Unconscious 
ness 
  Dryness of 
the skin, 
Body Pain, 
Back and hip 
Pain,Fever, 
Stupor 
 
 
Uyir Thathukkal 
Knowledge of three Uyir thathus and seven Udal Kattugal will be helpful to 
do detailed study on the disease. 
 
Vatham  
It is the life manifestation of Vayu and Ahaya boothams. Vatham located in 
the abanan, face, idakalai, spermatic cord, Pelvic bone, skin, nerves, joints, hairs and 
muscles 
 
Functions of Vatham 
Types of Vatham; It has 10 types; 
1. Pranan (Uyir Kaal) 
It is responsible for respiration and helps in assimilation of foods intaken.  
2. Abanan (Keezhnokku Kaal) 
It lies below the umbilicus and responsible for the downward by excreting the 
faecal matter and urine. It gathers and carries the anna saram to the proper 
places. 
3. Viyanan (Paravu Kaal) 
It is responsible for the action of all organs, sensation and it protects the body 
by filling the essences of the digested food in the proper places. 
4. Uthanan (Melnokku Kaal)  
It starts from Udharaakkini and travels with the essence of digested food and 
stops them in the proper places, it stirs and clear them.  
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5. Samanan (Nadu Kaal) 
It controls all other vayus. It helps us smoothening the food, liquids and makes 
softening the six tastes and helps in spreading them in the body.  
6. Nagan 
It is responsible for the higher intellectual functions. It brightens the intellect to 
learn all the arts and sciences; it helps in opening and twinkling of the eyes. 
7. Koorman:  
It starts from the mind and makes the eyes to twinkle; it yawns; it gives 
strength; it helps in opening and closing of the eyes. 
8. Kirukaran: 
It dwells in the tongue and gives greasiness and moisture to the tongue and the 
nose. It stimulates hunger. It helps in remembering things, it helps in creating 
sneezing and coughing, which is responsible for taste sense. 
9. Devathathan: 
It starts like arch and causes laziness and to squeeze the body in laziness. 
Immediately after awakening from sleep, it gives languor. It is responsible for 
tolerance, temperament for fighting, argument and furty.  
10. Thanajayan: 
It escapes from the head on the third day after death. 
 
Pitham 
It is the life manifestation of the bootham. Its mathirai is ½. 
Location of Pitham in the body 
Pitham is located in Pingali Pirana Vayu, blood, Moolakini, heart, Umblicus, 
abdomen, Sweating, saliva, eyes and skin. 
Functions of Pitham 
Pitham controls digestion, temperature, vision, appetite, thirst, taste and strength 
of the body.It is responsible for the formation of red or yellow colour in the body and 
heat especially during digestion. It is also responsible for giddiness, increase of blood, 
discolouration of stools, urine, anger, memory and bitter and sour taste. 
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1. Anal Pitham 
Its action is characteristic of thee. This is responsible for digestion of food.  
2. Ranjaga Pitham 
It is responsible for the colour and contents of the blood. 
3. Saathagam 
It lies in the heart. It is responsible for the action after thinking.. 
4. Prasagam 
It is responsible for the complexion of skin. 
5. Aalosagam 
It is responsible for the vision. 
Some patients affected causes defective vision. 
 
Kabam 
It is the life manifestation of Mann and Neer. It is mathirai‟s is ¼. 
Location of Kabam 
Kabam is located in Samana Vayu, Sperm, head, tongue, vulva, fat, bone 
marrow, blood, nose, chest, nerve, bone brain, eyes and joint and it provides the 
material for the structure of every cell of the body. 
Functions of Kabam 
Generally it acts as a destructive factor in the body. When Kabam is in normal 
condition, itmaintains heart function, taste, coolness of eyes, lubricates and aids free 
movements of the joints. 
1. Avalambagam 
It causes diseases of the respiratory system when it is affected thereby indirectly 
affecting the other Iyyams. 
2. Kilethagam 
Appetite and digestion may not be normal when it is affected. 
3. Pothagam 
It is present in the tongue and gives and taste.. 
4. Tharpagam 
Memory and perception of senses may be affected when this is deranged. 
5. Sandhigam 
It is present in the joints and helps free movements. 
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Ezhu Udal Kattugal 
There are seven primary body tissues which constitute the entire human body 
and all the organs of the various systems. 
1. Saaram 
It is the end product of digestive process. It gives strength to the body and mind. 
2. Senneer 
The saram after absorption is converted into seneer. It is responsible for 
knowledge, strength and health complexion. 
3. Oon 
It gives figure and shape to the body. It is responsible for the movement of the 
body.It lubricates the organs and thus facilitates their function. 
5. Enbu 
Gives shape to the body helps locomotion and protects vital organs. 
6. Moolai / Machai 
Present in the bone and it gives strength, maintains the normal condition of the 
bone. 
7. Sukkilam / Suronitham 
Responsible for reproduction. 
 
Piniyari Muraimai 
The method adopted to find out a disease in Siddha is known as PINIYARI 
MURAIMAI. It is based on the following principles. 
 Poriyal Arithal 
 Pulanaal Therthal 
 Vinavuthal 
“Pori” is the five organs of perception namely Nose, Tongue, Eyes, Ears and skin. 
“Pulan” is the five objects of senses smell. Taste, vision, auditory and sensation 
respectively corresponding to “Pori”. Proiyalarithal and Pulanal Therthal go hand in 
hand with the concept to examining the patients “Pori” and “Pulan” with that of the 
“Patients. Pori and Physicians Pulan”. “Vinathal” is a method of inquiring the details 
of either the patient‟s problem that made him to approach the physician from his own 
or his/her attenders who accompany them. The Primi method adapted to diagnostic 
the disease is by means of “Envagai Thervugal” (Eight types of investigation)  
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Envagai Thervugal Constitute: 
1. Naa 
2. Niram 
3. Mozhi 
4. Vizhi 
5. Sparism 
6. Malam 
7. Moothiram 
8. Naadi 
1. Naa 
 The colour character and condition of the tongue change according to the 
changes of 
Mukkutram. 
2. Niram 
 Signs of Vatha, Pitha, Kaba, colours, mixed colour cyanosis, Pallor; flushing 
or yellowish discolouration can be studies by means of Niram. 
3. Mozhi 
 Constitues high or low pitched voice, slurring and incoherent speech, nasal or 
crying & Hoarseness of voice etc. 
4. Vizhi 
 Along with sight, anatomical lesions are noted. Burning of the eyes, 
lacrimation, irritation colour change of the eyes also noted. 
5. Sparism 
 By palpation and inspection, the following informtion‟s were elicited. 
Temperature of the skin, whether uniformly hot or cold, thickness, fissures stuff / hard 
swelling, wrinkles, pigmentation of hairs etc. 
6. Malam 
 Vatha Type: Hard, rough, dry, scanty and black 
 Pitha Type: loose stools with yellow colour, moderate in quantity 
 Kapha Type: gray or white coloured stools, huge in quantity with Slimy, 
 mucus and Frothy bubbles. 
7. Moothiram 
 Colour, quantity, froth, thickness, odour, frequency, retention or obstruction 
signs. 
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8. Naadi 
 Naadi is responsible for the existence of life can be felt one inch below the 
wrist on the radical side by means of palpation with the tips of index , middle and ring 
finger , Corresponding to vatham, pitham, Kabam. Three humors of vatham, pitham, 
kabam exists in the ratios 1:1/2:1/4 normally. Dearrangement in these ratios leads to 
various diseases entities 
1. “tspehb ,lj;jpypire;jhy; tspFd;kkhk;” 
 “gpj;jehb ,lj;jpypire;jhy; gpj;jFd;kkhk;” 
 “fgehb ,lj;jpypire;jhy; fgFd;kkhk;” 
       - nghJ kUj;Jtk; 
2. “thje;jhd; cjwpepw;fpy; 
  typFd;kk;te;JNrUk;” 
       - nghJ kUj;Jtk; 
3. “thjKk;gpj;jKk;$b 
  td;ngyj;JlNdNahby; 
 jPjWtapw;WDs;Ns 
  jpuz;lNjhh;ke;jk;gw;wp 
 Ntjidnahpg;Gq;$b 
  ntUz;bLnkhpj;jFd;kk;” 
       - nghJ kUj;Jtk; 
4. “gpj;jj;jhy;gpj;jFd;kk; 
 vhpFd;kk;rj;jpFd;kKz;lhFk;” 
       - nghJ kUj;Jtk; 
5. “thjnkDk;ehbaJnjhd;wpy; 
 rPjke;jnkhLtapWg;nghUky;jpul;rpthA 
 …………………………………………… 
 ePjKWq;fpUkpFd;kk; mz;lthjk;” 
       - nghJ kUj;Jtk; 
6. “rpwg;ghdgpj;jj;jpy;thjehb 
 NrhpYWjhJel;lKjugPil 
 ciug;ghfr;nrhpahikFd;k#iy” 
       - nghJ kUj;Jtk; 
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2.3.7. czTg;gof;f tof;;fq;fs;  
cztpy; NrHf;f Ntz;bait : 
xU tUlk; nrd;w rpfg;ghprp rhg;ghL> fw;fz;L> kpUf khkpr urk;> 
gRk;ghy;> Ml;Lg;ghy;> NkhH> nts;isg;g+z;L> Rf;F> ngUq;fhak;> c\;z> 
,yF jPgz czTfs;> jpuhl;ir> vYkpr;rk; gok;> NghPr;rk;gok;> khJsk;gok;> 
,sKs;sq;fp> KUq;if> Mkzf;nfz;nza;. 
 
cztpy; jtpHf;fNtz;bait : 
cyHe;j khkprq;fs;> kPd;fs;> jpj;jpg;ghd gz;lq;fs;> Gjpa jhdpaq;fs;> 
Ks;sq;fp> thA rk;ge;jkhd> kyge;jfukhd md;dq;fs;.  
 
nra;a Ntz;ba nray;fs; : 
 grp NeHe;j Neuj;jpy; mjid clNd jFe;j czthjpfshy; 
jzpf;fNtz;Lk;. 
 mjpf grp NeHe;j fhyj;jpy; nea;g;Gg; gir cs;sJkhd czit 
cz;z Ntz;Lk;. 
o fhiy czT 7.30 – 8.30 
o kjpa czT 12.30 – 2.00 
o ,uT czT 7.00 – 8.00 
 ,U kyq;fis fopj;j gpd;dNu cztUe;j Ntz;Lk;. 
 ke;jj;jhy; Vw;gLk; GspNag;gk; ,y;yhj epiyapy; czT cl;nfhs;s 
Ntz;Lk;. 
 Fspj;jpUe;jhYk; kWgbAk; Kfk;> if fhy;fis ed;wha; J}a;ik 
nra;J nfhz;l gpd;dNu cztUe;j Ntz;Lk;. 
 cz;;Zk; NghJ cztpy; kdij nrYj;jp NtWtifapy; vz;zj;ijg; 
nrYj;jhky; cl;nfhs;s Ntz;Lk;. 
 czTf;Fg; gpd; jFe;jstpy; nte;ePH mUe;jNtz;Lk;. 
 
nra;af;$lhj nray;fs; : 
 czT cz;lTld; mjpf mstpy; ePH mUe;j $lhJ. 
 kyk;> %j;jpuk;> fz;zPH ,itfis jLj;jy; $lhJ. 
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2.4 MODERN ASPECTS 
PEPTIC ULCER DISEASE 
Peptic ulcers are the areas of degeneration and necrosis of gastrointestinal 
mucosa exposed to acid-peptic secretions mainly digestive action of gastric juice. 
Though they can occur at any level of the alimentary tract that is exposed to 
hydrochloric acid and pepsin, they occur most commonly (98- 99%) in either the 
duodenum (Duodenal ulcer) or the stomach (Gastric ulcer) in the ratio of 4:1. Each of 
the two main types may be acute or chronic. 
Figure 2.4a: Peptic ulcer 
Epidemology 
The epidemiology of PUD in India may have changed in the past two decades 
with the incidence of duodenal ulcer declining more rapidly than that of gastric ulcer. 
By 2020, 4,50,000 people will be severely affected or die from its 
complications.Indian Council of Medical Research (ICMR) conducted Population 
Surveys and the Multicentric study on the prevalence of peptic ulcer. The lifetime 
prevalence of the peptic ulcer was 0.61% in Delhi, 0.69% in Chandigarh, and 0.75% 
in Chennai. The Point prevalence of peptic ulcer in India was 4.72% and the lifetime 
prevalence was 11-22%. 
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Gastric ulcer 
Incidence 
I. Less common than duodenal ulcers 
II. Usually beyond 6thdecade 
III. More common in males than in females(3.5:1) 
 Etiology 
Gastric colonisation with H.pylori is usually asymptomatic but it leads to 
higher chances of development of duodenal ulcer. Disruption of mucus barrier is the 
most important factor.Association with gastritis, bile reflux, drugs, alcohol, tobacco 
will also leads to Gastric Ulcer. 
Pathogenesis 
 The development of peptic ulcer depends on the interplay of the following   
injurious and protective factors. 
Injurious factors 
 1. Endogenous -Acid, Pepsin, Bile acids 
 2. Exogenous -Ethanol, Aspirin, Other NSAIDs 
Protective factors 
Gastro mucosal barrier – Mucus 
Cyto protection a) Surface bicarbonate 
b) Hydro phobic layer 
c) Mucosal blood flow 
d) Alkaline tide 
e) Epithelial renewal 
f) Restitution 
g) Prostogladins 
h) Epidermal growth factor 
Pathologic Changes 
a. Most common along the lesser curvature and pyloricantrum 
b. Grossly similar to duodenalulcer 
c. Histologically, indistinguishable from duodenalulcer 
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ClinicalFeatures 
 Food-pain pattern 
 No nightpain 
 Vomiting common 
 Haematemesis more common 
 Significant loss of weight 
 Patients choose bland diet devoid of fried foods, curries etc. 
 Deep tenderness in the midline inepigastrium 
 No seasonal variation 
 More often in laboring groups  
 
Figure 2.4b: Pathogenesis of Peptic Ulcer 
 
 
Duodenal ulcer 
Incidence 
 Four times more common than gastric ulcers 
 Usual age 25-50 years 
 More common in males than in females(4:1) 
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Etiology 
 Most commonly as a result of H.pylori infection other factors hyper secretion 
of acid-pepsin, association with alcoholic cirrhosis, tobacco, hyperparathyroidism, 
chronic pancreatitis, blood group O, genetic factors. 
Pathogenesis 
 Mucosal digestion from hyperacidity most significant factor 
 Protective gastric mucus barrier may bedamaged 
Pathologic changes 
Most common in the first part of duodenum often solitary, 1-2.5 cm in size, 
round to oval, punchedout. Histologically, composed of 4 layers – necrotic, 
superficial exudative, granulation tissue andcicatrisation 
Clinical features 
I. Pain food- relief pattern 
II. Night pain common 
III. No vomiting 
IV. Malena more common than haematemesis 
V. No loss of weight 
VI. No particular choice of diet 
VII. Deep tenderness in the right hypochondrium 
VIII. Marked seasonal variation occurs more commonly in people at greater stress. 
Endoscopic Differentiation between Benign and Malignant Ulcer 
Signs of malignancy 
 Presence of an ulcer within a definite mass 
 Effaced, interrupted, fused or nodular mucosal folds as they approach margin 
of the crater. 
 Irregular filling defects in the ulcer crater. 
 Friability of ulcer and easy tendency to bleed. 
Signs of Benign ulcer 
 The mucosal folds, as they approach the edge of the ulcer crater, were seen to 
be smooth and symmetrical. 
 A smooth mound of oedema surrounding the ulcer. 
 Smooth translucent band or collar surrounding the ulcer crater. 
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Endoscopy 
Upper Gastrointestinal Endoscopy 
Indications 
 Dysphagia 
 Caustic or Foreign Body indigestion 
 Dyspepsia 
 Persistant nausea and vomiting 
 Need to obtain small intestine biospsy 
 Acute or Chronic gastrointestinal bleeding 
 Inflammatory bowel disease (as this may be associated) with duodenal   
Lesions mimicking a duodenal ulcer 
 Chronic abdominal pain 
 Suspected polyp or cancer 
 
Complications of Endoscopy 
 Perforation of viscus 
 Bleeding 
 Cardiac arrhythmias 
 Reaction to medication (sclerosants) 
 Vasovagal reaction 
 Pulmonary aspiration  
Complications of Peptic ulcer disease 
1. Upper GI bleed 
2. Perforation 
3. Gastric outlet obstruction and fluid and electrolyte imbalance 
4. Malignancy (with gastric ulcer less than 1% only) 
5. Pancreatitis 
6. Gastro-colic fistula 
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CHAPTER - III 
MATERIALS AND METHODS 
 
3.1 STUDY AREA AND SETTING 
The study period was covered from June 2017 to July 2019 at the Govt. 
Siddha Medical College and Hospital, Palayamkottai- 627 002, Tirunelveli, Tamil 
Nadu. All procedures were carried out after getting the permission from Institutional 
Ethical Committee.  
 
3.2 STUDY DESIGN 
 The study design is “a prospective open labeled non-randomized Phase-II 
clinical trial” of 40 Eri Gunmam (Peptic Ulcer Disease) subjects. The included 
subjects were newly diagnosed or already diagnosed as Ulcer patients with or without 
taking treatment.  A written informed consent form was recruited in the study. The 
purpose of the study was explained to the patients before administration of trial drug. 
The patient‟s basic information, life style and siddha parameters were recorded before 
starting the treatment.   
 The total number of 40 patients of both sex, ages between 20-60 was taken for 
this study. The selected patients were treated with the trial drug for the study period 
(30 days). 
 
3.3 SELECTION OF PATIENTS 
I selected the patients according to proforma. The criteria for selection of 
patients are given below (3.3.1). After inclusion of cases, screening is done before 
starting the treatment.  
Detailed personal history, family history, occupation, habits, clinical 
symptoms, medical history, and the duration of illness were recorded in all patients. 
3.3.1 Inclusion Criteria 
The parameters for the selection were as follows; 
o Age : 20 – 60 Years 
o Sex : Both male and female 
o Patients having appropriate symptoms of 
 Burning sensation in upper abdomen (Siru vayittril erichal) 
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 Nausea (Kudal kumattal) 
 Water brash (Vayil neer ooral) 
 Headache (Thalaivali) 
 Flatulence (Vayiruppal, Eraichal) 
 Dizziness (Kirukiruppu) 
 Excessive sweating (Mayirkalil viyarvai peruguthal) 
 Loss of body weight (Udal ilaithal) 
 Loss of appetite (Pasiyinmai) 
 Neuritic pain (Udal erichal) 
 Cough (Irumal) 
 Patient with Clinical Assessment Score ≥ 2.  
 Patient willing to sign the informed consent indicating that they understand the 
purpose and procedures required for the study and are willing to participate in 
the study. 
3.3.2 Exclusion Criteria 
Patients are excluded in the following conditions  
1. H/o. Pregnancy & lactation 
2. H/o. Recent Malignancy or Radiation Therapy 
3. H/o. Haemetemesis or Melena 
4. H/o. Pancreatitis 
5. H/o. Inflammatory Bowel disease 
6. H/o. Gastro oesophageal reflux diseases 
7. H/o. Systemic Hypertension 
 
3.4 TESTS AND ASSESSMENTS 
A. CLINICAL ASSESSMENT 
B. SIDDHA ASSESSMENT 
C. LABORATORY INVESTIGATIONS 
3.4.1 Clinical Assessment 
Clinical Assessment Score 
1. Burning sensation in upper abdomen (Siru vayittril erichal) 
2. Nausea (Kudal kumattal) 
3. Water brash (Vayil neer ooral) 
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4. Headache (Thalaivali) 
5. Flatulence (Vayiruppal, Eraichal) 
6. Dizziness (Kirukiruppu) 
7. Excessive sweating (Mayirkalil viyarvai peruguthal) 
8. Loss of body weight (Udal ilaithal) 
9. Loss of appetite (Pasiyinmai) 
10. Neuritic pain (Udal erichal) 
11. Cough (Irumal) 
 
Clinical Assessment Score = Number of present symptoms × 100      
                                                  Total number of symptoms 
3.4.2 Siddha Assessment 
 Kaalam  
 Nilam  
 Imporigal 
 Kanmentherium 
 Mukkutra nilaigal 
 Ezhu udarthathukkal 
 Kosangal 
 Envagaithervu 
 14 vegangal 
 Udarthee 
 Thegi Ilakkanam 
 Gunam 
 Manikadainool 
 
3.4.3 Lab Investigations 
Blood - Complete blood analysis TC, DC, ESR, Hb, TRBC, Blood Sugar, 
Blood urea, Serum Cholesterol, Creatinine, 
 
RoutineUrineAnalysis- Albumin, Sugar, Deposits, 
The Lab investigations were carried out before and after administration of trial  
drug.  
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3.5 TREATMENT 
3.5.1 Preparation of Trial Medicine (Annexure) 
 The Vellarugu Chooranam was selected from the Classical Siddha literature. 
Reference: “Gunapadam Mooligai Mudhal Vagupu”- Page No: 843. 
Author: K.S.Murugesa Mudhaliyar 
 
3.5.2 Collection and authentication of trial Medicine (Annexure) 
 Plant material was freshly collected from in and around Palayamkottai, 
Tirunelveli, Tamilnadu. It was identified and authenticated by the Medicinal Botanist 
Dr.S.Sutha, Ph.D., Associate Professor, Department Of Medicinal Botany at 
Government Siddha Medical College and Hospital, Palayamkottai. Purification of 
plant material and preparation of the medicine was executed in the P.G Gunapadam 
Practical lab of Govt. siddha medical college, Palayamkottai. 
 
3.5.3  Preclinical Analysis of trial Medicine 
                All the preclinical studies of the study drug, which includes Bio chemical 
and pharmacological studies, were carried out and results were cross checked before 
starting the treatment. 
A. Biochemical Analysis - It was done in Dept.of Biochemistry, GSMCH, 
Palayamkottai  
B. Phytochemical Analysis - Phytochemical analysis were done in K.M.College of 
Pharmacy, Madurai, Tamil nadu. The qualitative phytochemical analysis was 
carried out for major compound of interest such as Alkaloids, Flavanoids, 
Saponins, Phenol, Steroids, Glycosides, Tannins and Terpenoids. The analysis of 
phytochemicals has followed by Harborne and Onwukaemeand coworkers, 1999. 
The Quantitative estimation was done through spectrophotometric method for 
alkaloids estimation and FolinCio-calteau method for phenols.  
C. Antimicrobial assay -       
 Antimicrobial activity was carried out in Inbiotics lab, Nagercoil. 
 It was done by using Agar well diffusion method. 
 Materials required for this study were, 
 Antibacterial activity - Muller Hinton agar medium(1L), Nutrient 
broth(1L), Streptomycin(10mg/ml), Culture of test organisms - E.coli, 
Bacillus Subtilis, Klebsiella pneumonia, Streptococcus mutans and 
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Staphylococcus aureus (growth of culture adjusted according to 
McFarland Standard, 0.5%) 
 Antifungal activity - Potato Dextrose Agar Medium (1 L), Clotrimazole 
(standard antifungal agent, concentration: 10mg / ml), Culture of test 
organisms - Aspergillus Niger, Candida albicans (growth of culture 
adjusted according to McFarland Standard, 0.5%) 
D. Pharmacological studies - The Antiulcer, Anti spasmodic, Analgesic, Anti-
Inflammatory studies of the trial medicine was done in K.M.College of Pharmacy, 
Madurai, Tamil nadu.  
E. Toxicity study - Acute toxicity and sub acute toxicity of Vellarugu Chooranam 
carried out as per OECD-423 guidelines after the animal ethical clearance from 
Institutional Animal Ethics Committee. Toxicity studies were done in K.M 
College of Pharmacy, Madurai, and Tamilnadu.  
 
3.5.4 ETHICAL REVIEW   
 The study was conducted in accordance with the ethical principles that are 
consistent with Good Clinical Practice guidelines and prior approvals was obtained 
before starting of the trial from the Institutional Ethical Committee of GSMCH, 
Palayamkottai (GSMC-IV-IEC/2017/Br-I/05/29.05.2017) and & Institutional 
Animal Ethical Committee (IAEC) (approval number is 321611005/KMCP/27/2018). 
The study was registered in Clinical Trials Registry – India (CTRI) and the 
registration number is CTRI/2018/04/012924. (Annexure)  
 
3.5.5 STUDY ENROLMENT   
An open labeled non-randomized phase II clinical trial on Vellarugu 
Chooranam for Erigunmam was conducted in Government Siddha Medical College 
and Hospital, Palayamkottai, Tirunelveli. Totally forty cases were selected. 20 
patients were treated as OP; remaining 20 patients were treated as IP. The clinical 
signs and symptoms of VellaruguChooranam of both sexes were selected and studied 
under the guidance of the professor, reader and lecturer of P.G. Pothu Maruthuvam 
Department. 
Participants were informed in Tamil language, regarding the trial, the expected 
benefits and their right to opt-out of trial at any time without prejudice. Informed 
written consent was obtained from each participant, prior to his/her inclusion into the 
trial.  
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3.5.6  Withdrawal Criteria: 
 Intolerance to the drug and development of adverse reactions during 
drug trial. 
 Poor patient compliance and defaulters.  
 Patient turned unwilling to continue in the course of clinical trial. 
 Occurrence of any serious illness. 
During the visit, body weight, blood pressure, cardiovascular and respiratory 
system were clinically recorded. During the treatment, if any adverse reaction or side 
effects of patients, immediately inform patient and pharmacovigilence committee. At 
the end of the study period, all the patients were instructed to follow diet. They were 
also advised to pursue the further treatment in the PG, Pothu Maruthuvam OP for the 
follow up study. 
 
3.5.7  Outcome  
Grade: 0 - Clinically cured      CAS=0-5  
Grade: 1 - Clinically well improved    CAS=6-10  
Grade: 2 - Marginal clinical improvement  CAS=11-40  
Grade: 3 - Mild clinical improvement   CAS=41-70  
Grade: 4 - No changes clinically     CAS ≥70 
 
3.5.8  Statistical Analysis  
All data were analysed using the SPSS 20.0 (IBM). Data were expressed as 
means and standard deviations. The significance of the difference between the means 
of the baseline and the final clinical assessment were tested using the paired “t” test. 
A probability value of <0.05 was considered to be statistically significant. 
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CHAPTER - IV 
RESULTS AND OBSERVATIONS 
4.1. PRECLINICAL STUDY  
4.1.1 BIO-CHEMICAL ANALYSIS OF “VELLARUGU CHOORANAM” 
 Preparation of the extract: 5gms of chooranam was weighed accurately 
and placed in a 250ml clean beaker then 50ml of distilled water was added and 
dissolved well. Then it was boiled well for about 10 minutes.  It was cooled and 
filtered in a 100ml volumetric flask and then it was made up to 100ml with distilled 
water. This fluid was taken foranalysis. 
Table 4.1.1 Qualitative Analysis of Vellarugu Chooranam 
S. 
No. 
Experiment Observation Inference 
1. Test for calcium 
A white precipitate 
was formed 
presence of 
calcium 
2. Test for sulphate 
A white precipitate 
was formed 
presence of 
sulphate 
3. Test for chloride 
A white precipitate 
was formed 
presence of 
chloride 
4. Test for carbonate 
No brisk effervesesence 
was formed 
Absence of 
carbonate 
5. Test for starch Blue colour was formed presence of starch 
6. Test for ferriciron 
No Blue colour was 
formed. 
Absence of Ferric 
Iron. 
7. Test for ferrousiron 
Blood red colour was 
formed. 
Presence of 
Ferrous Iron. 
8. Test for phosphate 
No yellow precipitate 
was formed. 
Absence of 
phosphate. 
9. Test for albumin 
No yellow precipitate 
was formed. 
Absence of 
Albumin. 
10. Test for tannic acid 
No blue black 
Precipitate was formed. 
Absence of 
Tannic acid. 
11. Test for unsaturation It  gets decolouristd 
Presence of 
unsaturated 
compound. 
12. 
Test for the reducing 
sugar 
No colour change 
occurs. 
Absence of 
Reducing sugar. 
13. Test for amino acid 
Violet colour was 
formed. 
Presence of 
Amino acid. 
14. Test for zinc 
No white precipitate was 
formed 
Absence of Zinc. 
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Inference: 
 Presence of Calcium, Sulphate, Chloride, Starch, FerrousIron, Unsaturated 
compound and AmnioAcid. 
 
4.1.2 PHYTOCHEMICAL ANALYSIS OF “VELLARUGU CHOORANAM” 
The VC was subjected to qualitative chemical investigation. Details of the 
various tests performed for the presence of phyto constituents is shown in Table 4.1.2. 
 
Table 4.1.2 Phytoconstituents of Vellarugu Chooranam 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Tests VC 
Alkaloids  
Mayer‟s test  Present 
Dragendroff‟s test  Present 
Hager‟s test  Present 
Carbohydrates and glycosides  
Molisch test  Present 
Legal‟s test  Present 
Borntrager‟s test for anthraquinones  Present 
Phytosterols  
Liebermann-Burchard test  Present 
Salkowski test  Present 
Flavanoids  
Shinoda test  
Magnesium turnings and hydrochloric acid (Presence of red color)  
Present 
Fluorescence test  Present 
Tannins  
Ferric chloride test  Present 
Potassium dichromate test  Present 
Lead acetate test  Present 
Proteins  
Millon‟s test  Present 
Biuret test  Present 
Ninhydrin test  Present 
Fixed oils and fats  
Spot test  Absent 
Saponification test  Absent 
Lignin  
Phloroglucinol test  Present 
Saponins  
Frothing test  Absent 
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Inference: 
 The Phytochemical screening of poly herbal formulation of VC showed the 
presence of Alkaloids, Carbohydrates and Glycosides, Phytosterols, Flavanoids, 
Tannins, Proteins, Lignin, Saponins. 
4.1.3 ANTIMICROBIAL ANALYSIS OF VC 
Table 4.1.3 Anti microbial Activity of VC 
Sample 
Code 
Bacteria  Strains Name 
Staphylococcus 
aureus (G+) 
Streptococcus 
mutans (G+) 
Bacillus 
subtili(G+) 
Klebsilla 
pneumonia(G-) 
E.coli 
(G-) 
VC 15 8 11 10 10 
PC 27 17 14 28 18 
NC - - - - - 
 
Keys 
             PC   -     Positive Control (Streptomycin) 
NC        -    Negative Control 
 -           -    No Zone 
Mm       -    Millimetre  
             G+        -   Gram Positive Organism 
             G-         -   Gram Negative Organism 
Inference: 
Trial drug showed the anti microbial activity against (MIC) both Gram 
positive bacteria (Staphylococcus aureus, Streptococcus mutans, and Bacillus subtilis) 
and Gram negative bacteria (Klebsilla pneumonia, E.coli). 
 
4.1.4. PHARMACOLOGICAL STUDIES 
4.1.4.1. ANTI ULCER ACTIVITY OF VELLARUGU CHOORANAM 
Male Albino rats (180-220 gm) were feed a standard diet and water ad libitum. 
Gastric lesions were induced by administration of Acetyl salicylic acid at 200mg/ kg 
orally. The animals were housed in groups of five, each contains six animals and 
accommodated to room condition for at least two days before the experiments. Food 
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and water were freely available up to the experiments. The food was withdrawn on 
the day before the experiment, but free access to water was allowed. 
 
Table 4.1.4.1a Experimental Design Anti-Ulcer Activity 
GROUP NO TREATMENT DRUG /DOSE 
Group-I NORMAL CONTROL CMC 1% ( 1ml) 
Group-II ULCER CONTROL ASA 200mg/ kg 
Group-III STANDARD CONTROL 
OMEPRAZOLE  2mg /kg (Half 
hour before ASA administration) 
Group-IV TREATMENT CONTROL 
VC100mg/kg orally (Half  hr 
before ASA administration) 
Group-V TREATMENT CONTROL 
VC 200mg/kg orally (Half  hr 
before ASA administration) 
 
Aspirin Induced &Pyloric Ligation Ulcer Model  
The albino rats were divided in to five groups, each group contains six 
animals. The study was carried out for four days, after administration of the treated 
dose 30 minafter; the rats were treated with aspirin 200mg /kg.  This process was 
carried out for three days, on the third day after administration of drug the rats were 
subjected to fasting. On the next day pyloric ligation was made. The rats were 
sacrificed four hrs later by cervical dislocation and the esophagi were clamped, the 
stomach was exposed carefully, opened along the greater curvature, the luminal 
contents were removed, the total volume of gastric secretion, total acidity, free acidity 
were estimated by titration method. The ulcer index was calculated according to the 
method of gangrly and Bhatnagar. The lesions were counted with the aid of hand lens 
(10x) and each gives a severity rating as follows. 
 
Table 4.1.4.1b Ulcer Score  
 
ULCER  
SCORE 
DESCRIPTIVE 
OBSERVATION 
0 Normal colored stomach 
0.5 Red coloration 
1 Spot ulcers 
1.5 Haemorrhagic  streak 
2 Ulcers 
3 Perforation 
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Mean ulcer score for each animal was expressed as ulcer index. The 
percentage of ulcer inhibition was determined as follows  
Protection of ulcer (%) =   Control mean ulcer index- test mean ulcer index     × 100 
                                                           Control mean ulcer index  
# values are expressed as MEAN ± SEM, values were find out by using one way 
ANOVA followed by Newman  kevel‟s multiple range test, probability value  p< 0.01 
was considered significant. 
 
   Table 4.1.4.1c Antiulcer activity of VC 
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I Normal control 
1 ml of 
1%cmc 
3.5±       
0.58 
425.42±   
21.30 
2.2± 
0.19 
0.29± 
0.01 
0.000 
II Ulcer control 
200mg/kg 
ASA 
5.6±     
0.84
*a
 
488.45±
*a
  23.15
 
1.2±
*a
   
0.11 
2.0±
*a
   
0.15 
0.000
 
III 
Standard 
control 
2mg/kg 
omeprazole 
2.7±       
0.32 
330.85±    
15.30 
4.0±  
0.54 
0.50± 
0.05 
75.00 
IV 
Treatment 
control 
VC 
100mg/kg 
3.0±     
0.38
*b 
375.2±
*b
       
18.15 
3.0±
*b
  
0.28 
0.83±
*b
  
0.09 
58.50 
V 
Treatment 
control 
VC 
200mg/kg 
3.4±     
0.40
*b 
360.2±
*b
       
16.08 
2.4±
*b
  
0.28 
0.73±
*b
  
0.10 
63.50 
 
Values are expressed as Mean± SEM 
*a – Values are significantly different from Normal control group at P<0.01 
*b -- Values are significantly different from ulcer control group at P<0.01 
Results 
Administration of 200 mg/kg ASA suspension intragastrically consistently 
caused hemorrhagic lesions in the mucosa of the glandular stomach, indicating true 
ulcer formation as stated in histological findings. Pretreatment of rats with siddha 
formulation Vellarugu chooranam through orally at 100 and 200mg/kg prevented 
gastric ulcerogenesis significantly. However, it‟s seemed to be less efficient than 
standard drug like omeprazole. 
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4.1.4.2 ANTI-INFLAMMATORY AND ANALGESIC ACTIVITIES OF 
VELLARUGU CHOORANAM 
Acute Inflammatory Activity 
The Carrageenan-induced rat paw edema is used widely as a working model of 
inflammation in the search for new anti-inflammatory drug. The anti inflammatory 
activity of the Siddha formulation Vellarugu chooranam was evaluated by 
carrageenan-induced rat paw edema method. Albino Wistar rats (180 ± 5 g) were 
used. Anti inflammatory activity was measured using carrageenan induced rat paw 
edema assay. The rats were divided into 5 groups of 5 animals each. Group I were 
given normal saline and treated as negative control. Rats of Group II were treated 
with carrageenan (1%w/v) in saline in the subplantar region of the right hind paw. 
Rats in Group III were administered Indomethacin (10 mg/kg/bw) and considered as 
standard. Rats from Group IV and V were given two doses Siddha formulation (100 
and 200 mg/kg bw). Acute paw edema was induced by injecting 0.1 ml of 1% (w/v) 
carrageenan solution, pre-pared in normal saline. After 1 hr, 0.1 ml, 1% carrageenan 
suspension in 0.9% NaCl solution was injected into the sub-plantar tissue of the right 
hind paw. The linear paw circumference will be measured at hourly interval for 4 hr. 
The perimeter of paw was measured by using vernier callipers. Measurements were 
taken at 0–4 hr after the administration of the carrageenan.  
The anti-inflammatory activity was calculated by using the relation  
%inhibition of edema =   T − T0 X 100 
           T 
T-Thickness of paw in control group; T0-Thickness of paw edema in the test 
compound treated group. 
 
Carrageenan Induced Pleurisy in Rats 
The animals were divided into five groups of five rats each as described in the 
carrageenan induced paw edema model and each were pretreated with siddha 
formulation (100 and 200 mg/kg, p.o.), Indomethacin (10 mg/kg, p.o.) or normal 
saline (0.1 ml).One hour later all the animals were received 0.25 ml of an intrapleural 
injection of 1 % carrageenan on the right side of the thorax. The animals were 
sacrificed 3 h after carrageenan injection by ether inhalation. One ml of heparinized 
Hank‟s solution was injected into the pleural cavity and gently massaged to mix its 
47 
 
contents. The fluid was aspirated out of the cavity and the exudates were collected. 
The number of migrating leukocytes in the exudates was determined with Neubauer 
chamber. 
The values of each experimental group were expressed as mean ± SEM and 
compared with the control group. 
 
Analgesic Activity   
The acetic-acid writhing test was performed using the reported procedure 
Groups of rats (n=6), were administered with 100 and  200 mg/Kg of Siddha 
formulation Vellarugu chooranam, 10 mg/Kg Diclofenac as positive control group 
and 1 mL distilled water as negative control group. After 30 minutes the animals were 
administered with i.p. injection of 0.1 mL acetic acid (0.6%). Then the count of 
abdominal contractions of animals during 30 minutes after acetic acid injection was 
reported and the Percentage Analgesic Activity (PAA) was calculated by using the 
following formula: 
PAA = ((C- CD)/CD) ×100 
C = Mean of contractions count in animals treated with different doses of 
siddha formulation Vellarugu chooranam and Diclofenac sodium,  
CD = Mean of contractions count in animals served as negative control. 
 
Results 
The effect of siddha formulation Vellarugu chooranam on carrageenan-
induced edema in rats is shown in Table 4.1.4.2a. The results obtained indicate that 
the Siddha formulation Vellarugu chooranam had significant anti-inflammatory 
activity in rats. The siddha formulation Vellarugu chooranam was reduced the edema 
induced by carrageenan by 60.11% and 63.48% on oral administration of 100 and 200 
mg/kg, as compared to the untreated control group. Indomethacin at 10 mg/kg 
inhibited the oedema volume by 65.73%. 
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Table 4.1.4.2a Effect of VC on Carrageenan Induced Paw Edema in Rats. 
 
Treatment 
 
Dose (mg/kg, p.o.) 
Mean 
increase in 
paw 
volume(ml) 
% 
Decrease 
in paw 
volume 
Normal control 10ml/kg saline 1.12 ± 0.11  
Toxic control 0.1ml,1% Carrageenan 3.56±0.30*a  
Standard control 10mg/kg Indomethacin 1.22±0.14*b 65.73% 
Treatment control 100mg/kg VC 1.42 ± 0.19*b 60.11% 
Treatment control 200mg/kg VC 1.30 ± 0.16*b 63.48% 
 
Table 4.1.4.2 b Effect of VC on Carrageenan Induced Pleurisy in Rats. 
Treatment Dose (mg/kg, p.o.) 
Pleural 
exudates 
(ml) 
Leukocytes 
(×103cells/ml) 
Normal control 10ml/kg saline 0.16±0.08 0.40±0.05 
Toxic control 0.1 ml, 1% carrageenan 0.48±0.20*a 4.24±0.39*a 
Standard control 10mg/kg Indomethacin 0.18±0.10*b 0.48±0.08*b 
Treatment control 100mg/kg VC 0.24±0.13*b 0.58±0.12*b 
Treatment control 200mg/kg VC 0.20±0.11*b 0.50±0.09*b 
 
The administration of Vellarugu chooranam on carrageenan-induced pleurisy in 
rats was explained in Table 4.1.4.2b. The volume of pleural exudates in the toxic 
control group was reduced in 0.48±0.20 ml. Animals treated with the siddha 
formulation Vellarugu chooranam (100 and 200 mg/kg, p.o.) decreased the pleural 
exudates to 0.24±0.13 ml and 0.20±0.11.Treatment with Indomethacin (10 mg/kg, 
p.o.) produced the exudates of 0.18±0.10 ml. The leukocyte count for the control 
group was found to be 4.24±0.39×10
3
 cells/ml. Animals treated with the siddha 
formulation Vellarugu chooranam and   standard produced a leukocyte migration of 
0.58±0.12×10
3
, 0.50±0.09X10
3
 and 0.48±0.05×10
3
cells/ml, respectively. 
 
The study showed that the application of different doses of Siddha formulation 
Vellarugu chooranam had significant analgesic effects in the animals under 
investigation. The results of doses 100 and 200 mg/Kg were significant and 
comparable with the effect of Diclofenac sodium in analgesic activity. 
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Table 4.1.4.2c Effects of VC on acetic acid–induced writhing response 
Groups Treatment 
(number of writhing 
movements)(Mean±S.E) 
Percentage 
Group I Distilled water 29.00 ± 2.45  
Group II Diclofenac sodium 10mg/kg 6.08 ± 0.90*b 79.03% 
Group III 100mg/kg VC 14.25 ± 1.65*b 50.86% 
Group IV 200mg/kg VC 13.05 ± 1.30*b 55.00% 
 
* Values are expressed as mean ± SEM. 
 *b) Values are significantly different from Toxic control G2 at P<0.01. 
The results are reported as mean ± S.E.M. The statistical analyses were 
performed using one way analysis of variance (ANOVA). Group differences were 
calculated by post hoc analysis using Tukey‟s test. For all tests, differences with 
values of P<0.05 were considered significant. 
 
Discussion 
The tests performed with VC in the pleurisy model showed that VC 
behaves as an inhibitor of leukocyte migration and the formation of pleural exudates 
when given orally, as reported earlier. Thus it can be concluded that VCpossess 
significant anti-inflammatory activity in rats. Further studies involving the 
purification of the preparation and the investigations in the biochemical pathways 
may result in the development of a potent anti-inflammatory agent with a low toxicity 
and better therapeutic index. 
 
The analgesic activity was assessed by writhing test, which has been reported 
to be useful for investigation of peripheral anti nociceptive activity and performed as 
a chemical pain mode. The VCdemon treated a dose-dependent, significant anti 
nociceptive activity in animal models of pain. Acetic acid believed to increase the 
PGE2 and PGF2α in peritoneal fluid. The analgesic activity shown in models of pain 
is indicative VC might possess centrally and peripherally mediated anti nociceptive 
properties.  
 Chemical components of VC such as flavonoids, saponins or phenolic 
compounds may be responsible for the anti nociceptive activities of this formulation. 
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Since the findings of this study revealed a significant analgesic effect of the VC, it can 
be concluded that terpenoids and specially saponins of VC may be responsible for the 
observed analgesic effect which should be proved by further investigations.  
 
Conclusion 
It can be concluded that possesses anti-nociceptive properties which are 
probably mediated via inhibition of prostaglandin synthesis as well as central 
inhibitory mechanisms which may be of potential benefit for the management of pain 
and inflammatory disorders. 
 
4.1.4.3 INVITRO ANTI-SPASMODIC ACTIVITY OF VELLARUGU 
CHOORANAM 
Rats were anesthetized and sacrificed by euthanesia method followed by 
exsanguinations. The ileum was dissected out immensed in tyrode‟s solution and 
cleaned off the mesentry.respective segments of 2-3 cm long were mounted in a 30ml 
tissue inner organ bath filled with mixture of 95% o2 and 5% co2 and maintained at 
37
oc.the composition of tyrode‟s solutions (in mm for one litre) was 9mg KCl, 0.1mg 
NaCl 0.1mg nahco3, 0.42 mg NaH2PO4, 0.6mg glucose and ph value was 7.4. 
Dose response curve of acetylcholine were recorded with dose of 0.1, 0.2, 0.4, 
0.8, 1.6, 3.2(100mg/ml) using student organ bath, sheerington rotating drum with help 
of frontal writing lever. Contact time of 60sec and base line of 30 sec, time cycle were 
opted for proper recording of the responses in presence of tyrode‟s solutions as stock-i 
solutions.Then the same concentrations dependent responses of acetyl choline (ach) 
using same procedure for a mixture tyrode solutions with vellarugu chooranam with a 
concentrations of 1mg/ml as a stock-11 solutions were recorded.Lastly the same 
concentrations dependent responses of ach for a mixture of tyrode‟s solutions with 
atropine as standard (antispasmodic agents) as a stock iii solutions were recorded. 
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Discussion 
From the present study it was observed that acetylcholine alone causes 
contraction of excised rat ileum. But when acetyl choline was given in presence of 
vellarugu chooranam there was marked decrease in contraction of ileum was 
observed. This revealed that vellarugu chooranam possess a high degree of 
spasmolytic (anti-spasmolytic) by blocking cholinergic receptors. 
 
Conclusion 
From all observation and results obtained for the present study it was 
concluded that vellarugu chooranam exhibits promising anti-spasmodic activity also 
when compared with standard anti-spasmodic agent (atropine) it was found that 
vellarugu chooranam has comparatively less potent spasmolytic activity than atropine. 
 
Table no 4.1.4.3a Dose response relationship observation of acetylcholine. 
S.No Concentration/dose Ach response (cm) 
1 10/0.1 2.7 
2 20/0.2 3.3 
3 40/0.4 3.8 
4 80/0.8 4.3 
5 160/1.6 4.9 
6 320/3.2 5.5 
 
Table no 4.1.4.3b Dose response relationship observation of atropine 
S.No Concentration/dose Atropine response (cm) 
1 10/0.1 ------ 
2 20/0.2 ------ 
3 40/0.4 ------ 
4 80/0.8 ------ 
5 160/1.6 ------ 
6 320/3.2 ------ 
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Table no 4.1.4.3c Dose response relationship observation of ach and VC 
S.No Concentration/dose Ach +VC (cm) % response 
1 10/0.1 2.3 85.18% 
2 20/0.2 2.7 81.81% 
3 40/0.4 2.9 76.31% 
4 80/0.8 3.1 72.09% 
5 160/1.6 3.3 67.34% 
6 320/3.2 3.7 67.27% 
 
4.1.5. TOXICOLOGICAL STUDIES 
4.1.5.1. ACUTE AND SUB ACUTE TOXICITY OF VELLARUGU 
CHOORANAM 
Acute and Subacute Toxicity Studies:  
          Male and female Wister albino rat weighing 180 ± 10 g are used for the present 
study. The animals are divided into three groups of six animals, totally 18 animals 
were used in this acute toxicity study. The Group I animals are administered a single 
daily dose of 0.5 ml of Tween 80 orally for 15 days. In Group II are administered with 
(300 mg.kg
-1
b.w.VAC).once a day for 15 days. The Group III are administered 2000 
mg.kg
-1
b.w. of the VAC once daily for 15 days for acute toxicity studies.  
 
 In sub acute toxicity studies Wister albino rat weighing 180 ± 10 g  five 
groups were selected, totally 30 animals are used.  Group II to V animals weretreated  
50 mg,100,400 mg/kg/Bw once daily for 28 days .Where as Group I treated control 
group for this study.The group of animals was weighed every five days, The weight 
variation, Hematological parameters, the biochemical, serological analysis were 
carried out before and after studies. All studies were carried out under OECD -423 
guidelines. 
 
Results and Discussion 
Acute toxicity study for VC 
 There was no mortality or morbidity observed in animals through the 15-days 
period following single oral administration at all selected dose levels of the Vellarugu 
chooranam (VC). Acute toxicity study of Vellarugu chooranam (VC) on experimental 
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rat, noted in acute and mortality ratio. The animals did not show any physical changes 
in general appearance during the observation period. Morphological characteristics 
such as skin, eyes, and nose appeared normal. No tremors, convulsion, salivation, 
diarrhea, lethargy or unusual characters were observed.(Table no 4.1.5.1a.)  
Table no 4.1.5.1a. Sign of Acute toxicity and mortality ratio 
 Dose (mg.kg
-1
) Sign of Toxicity (ST.NB
-1
) Mortality (D.S
-1
) 
Group I              0                      0/3            0/3 
Group II            300                      0/3            0/3 
Group III           2000                      0/3             0/3 
 
ST- a sign of toxicity; NB- normal behavior; D- died; S- survive (n=3). 
 
Sub-acute Toxicity  
The effect of Vellarugu chooranam (VC) was observed for their effect on the 
body weight changes. From the study, it was observed that significant increase 
(p<0.05) in body weight in all the animals. The results are described in Table 4.1.5.1b 
The values are expressed as Mean ± S.E.M. n=6. The results of group I were 
compared with other groups such as II, III, IV, and V.   The statistical analysis was 
carried out using one way ANOVA method, where **P<0.01 *P<0.05. 
Table 4.1.5.1b Effects of VC on changes in body weight  
Treatment Day 1 Day 7 Day 14 Day 28 
Control 187.15±6.83 187.45  ±6.20 196.15 ±6.34 196.7±6.52 
VC 50 mg.kg
-1
 194.30 ±6.44 193.30  ±6.40 198.25 ±6.72 198.30±6.77
*
 
VC 100 mg.kg
-1
 186.35 ±5.74 189.30  ±6.30 196.55  ±7.17 197.36±6.33
*
 
VC 200 mg.kg
-1
 195.30  ±7.22 198.15±6.54 198.90  ±7.25
**
 206.45±7.28
**
 
VC 400 mg.kg
-1
 187.65  ±6.09 192.15 ±5.63 195.60  ±6.34
**
 207.66±7.39
**
 
 
 In Table no 4.1.5.1c. The effects of Vellarugu chooranam (VC) on kidney, 
heart, liver and brain of the rat were observed. From the study, it was clear that 
significant (p<0.01) changes in the weights of various organs of the animals occurred 
with higher doses of the extract (400 mg.kg
-1
bwt), but macroscopic examinations did 
not show any changes in colour of the organs of the treated animals compared with 
the control group. The values are expressed as mean ± S.E.M. n=6.   The results of 
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group I were compared with other groups such as II, III, IV, and V.  The statistical 
analysis was carried out using one way ANOVA method, where **P<0.01. 
 
Table no 4.1.5.1c Effects of VC on Changes in internal organs 
Treatment Heart (g) Kidney (g) Liver (g) Brain (g) 
Control 0.38 ± 0.05 0.67± 0.03 3.32± 0.05 0.68± 0.05 
VC 50mgKg
-1 
0.39± 0.02 0.83± 0.03 3.44± 0.03 0.71± 0.3 
VC 100 mg.kg
-1
 0.39± 0.06 0.81± 0.04 3.36±0.02 0.69± 0.2 
VC  200 mg.kg
-1
 0.38± 0.04 0.76± 0.02 3.34± 0.02 0.76± 0.05 
VC  400 mg.kg
-1
 0.37± 0.03 0.77± 0.03 3.37± 0.03 0.78± 0.05 
 
Effects of VC on Changes in Biochemical Lipid profiles 
  In table no 4.1.5.1d. Shows that animals has significant decrease (p<0.05) in 
the plasma glucose level in treated rat especially at higher dose (400 mg.kg
-1
) 
compared with other control groups. Significant decreased (p<0.05) in the plasma 
total cholesterol (TC), triglyceride (TG) and LDL-cholesterol levels were observed. 
But a significant increased (p<0.05) in HDL-cholesterol levels were observed in all 
the treated animals compared with the control animals.  
Table no 4.1.5.1e. AST, ALT and ALP levels were also normal in the VC. From the 
results of a biochemical study, there was no evidence of severe toxicity associated 
with the administration of higher concentration.The values are expressed as mean ± 
S.E.M. n=6.   The results of group I were compared with other groups such as II, III, 
IV, and V.  The statistical analysis was carried out using one way ANOVA method, 
where **P<0.01 *P<0.05. 
Table.4.1.5.1d Effects of VC on Changes in Biochemical Lipid profiles 
Treatment 
Glucose 
(mg.dl
-1
) 
Cholesterol 
(mg.dl
-1
) 
Triglyceride 
(mg.dl
-1
) 
HDL 
(mg.dl
-1
) 
LDL 
(mg.dl
-1
) 
Control 97.65± 0.62 42.62± 0.56 31.25± 0.45 138.25± 0.55 87.15±1.72 
VC 50 mg.kg-1 95.50± 0.56 28.85± 0.25* 16.22± 0.23* 178.28± 0.65* 74.59±1.28 
VC 100 mg.kg-1 92.45± 0.47 29.74± 0.26* 18.42± 0.28* 168.18±0.78* 72.84±1.10 
VC 200 mg.kg-1 93.25± 0.55** 35.18± 0.30 20.84± 0.38* 187.30± 0.84* 51.60±1.30 
VC 400 mg.kg-1 89.25± 0.45** 35.78± 0.28 22.28± 0.34* 185.2± 0.85* 49.50±0.84 
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Table 4.1.4.4e.The values are expressed as mean ± S.E.M. n=6. The results of group I 
were compared with other groups such as II, III, IV, and V. The statistical analysis 
was carried out using one way ANOVA method, where **P<0.01 *P<0.05. 
 
Table 4.1.5.1e Effects of VC on Changes in hepatic enzymes 
 
Treatment 
AST 
(IU.l
-1
) 
ALT 
(IU.l
-1
) 
ALP 
(IU.l
-1
) 
TP 
(g.l
-1
) 
ALBUMIN 
(g.l
-1
) 
Control 329.5±12.40 70.5± 3.18 246.58± 8.80 62.85± 3.32 42.15±2.35 
VC 50 mg.kg-1 318.0±9.50** 66.5± 2.20** 259.10± 2.75** 63.30± 2.32 39.30±2.65 
VC 100 mg.kg-1 319.3±7.20** 66.1± 3.15** 263.18± 6.70** 73.15± 2.82 41.30±3.05 
VC 200 mg.kg-1 314.4±7.95 61.4± 2.90 258.00± 5.20 62.25± 3.32 43.20±2.75 
VC 400 mg.kg-1 324.2± 8.20 63.3± 3.52 262.40± 4.40 67.05± 2.58 42.48±2.70 
 
Table 4.1.5.1f.The effects of VC were observed for its effect on hematological 
parameters in experimental rat. The final study, a significant increase (p<0.01)  in the 
hemoglobin, RBC  values were noted in after treated groups.There was no significant 
changes in the calcium level in all the treated animals compared to the control.The 
values are expressed as mean ± S.E.M. n=6. The results of group I were compared 
with other groups such as II, III, IV, and V. The statistical analysis was carried out 
using one way ANOVA method, where *P<0.05. 
 
Table 4.1.5.1f Hematological parameters Changes in rat 
Treatment 
Haemoglobin 
(gm.dl
-1
) 
RBC 
(10
6
 /mm
3
) 
WBC 
(10
6 
/mm
3
) 
Calcium 
(mg.dl
-1
) 
Control 11.3± 0.25 10.10± 0.02 12.4± 0.05 9.45 ±0.02 
VC 50 mg.kg-1 11.5± 0.35
*
 9.46± 0.45
*
 10.5± 0.13
*
 9.75 ±0.02 
VC 100 mg.kg-1 12.3± 0.15
*
 10.50± 0.02
*
 9.3± 0.32
*
 9.27 ±0.20 
VC 200 mg.kg-1 10.7± 0.20
*
 9.28± 0.12
*
 12.4± 0.03
*
 9.61 ±0.13 
VC l00 mg.kg-1 12.5± 0.26
*
 10.45± 0.04
*
 10.5± 0.01
*
 9.21 ±0.02 
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Discussion  
In the present study, where the acute toxicity study of Vellarugu chooranam 
(VC) was carried out as per OECD-423 guidelines. No mortality was observed in  
control group as well as treated groups animals,maximum dose of 2000 mg.kg
-1 
was 
not produced any toxicity.  Hence, 1/10
th
 of 2000 mgkg
-1
 i.e. 200 mg.kg
-1
 of dose was 
selected as a minimum dose for acute  toxicity study.  
The results of sub acute toxicity study shows that animals treated with VC 
showed normal growth pattern and body weight compared with control rats treated 
with normal saline. So the changes in body weight can be used as an indicator of 
adverse effects of drugs and chemicals. Serum cholesterol and proteins mainly 
regulated via synthesis in the liver and increase or decrease in serum concentrations of 
constituents suggest liver toxicity.   All test animals were subjected to gross necropsy 
.There was a slight decrease in plasma glucose level, when higher doses of VC 
(400mg.kg
-1
) were administered in the treated rats..The significant increase in the 
levels of hemoglobin (Hb) was found in treatment with VC with a higher dose of 
200mgkg
-1
. The possible reason could be that one of the constituents VC may increase 
absorption of iron.  
 
The overall results suggest that VC is non toxic to the haematopoietic and 
leucopoietic system. The haematopoietic and leucopoietic systems are the most 
sensitive targets for toxic compounds and an important index of physiological and 
pathological status in man and animal. Therefore, it is possible to assume that the VC 
is non haematotoxic effects.  
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4.2. CLINICAL STUDY 
40 Patients with the Clinical Assessment Score (Grade ≥2) were recruited to the 
treatment with the trial drug Vellarugu chooranam (30mg/kg/bw) twice a day 
orally before food. 
The following parameters are evaluated, which recorded at the time of 
enrolment 
1.  Gender distribution 
2. Age (Kaalam) distribution 
3. Occupational status 
4. Religion status 
5. Dietary Habits 
6. Dietary time habits 
7. Marital Status 
8. Personal Habits 
9. Nilam 
10. Kaalam (Season) 
11. Imporigal 
12. Kanmenthiriyam 
13. Uyir thathukal 
Vatham 
Pitham 
Kabam 
14. Udal thathukal  
Increased 
Decreased 
15. Kosangal 
16. Envagai thervugal 
Naadi 
Sparism, Naa, Niram, Mozhi, Vizhi, Malam 
17. Neerkuri 
 Niram 
 Manam, Edai, Nurai, Enjal 
18. Neikuri 
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19. Habits of controlling 14 Vegangal 
20. Udarthee 
21. Thegi Ilakkanam 
22. Gunam 
23. Manikadainool 
24. Distribution for clinical assessment  
Based on clinical symptoms before and after treatment 
Based on grade before and after treatment 
25. Difference analysis for   
Evaluating the significance between CAS and outcome 
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4.2.1: Gender 
Table 4.2.1: Distribution of Gender 
S. 
No 
Gender 
Out patients In patients 
No. of Cases Percentage 
No. of 
Cases 
Percentage 
1. Male 15 75% 10 50% 
2. Female 5 25% 10 50% 
 
Figure 4.2.1: Distribution of gender 
 
 
Inference: 
             From above table, In patients  of both male and female were equally affected,  
out patients 75% of male and 25% of female were affected. 
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4.2.2: Age 
 
Table 4.2.2: 
Distribution of Age 
 
S. 
No 
Age 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. 
Vathakaalam  
(0-33 years) 
6 30% 2 20% 
2. 
Pithakaalam  
(34-66 years) 
14 70% 18 80% 
3. 
Kabhakaalam 
(67-100 years) 
0 0% 0 0% 
 
    Figure 4.2.2:  
Distribution of Age 
 
 
Inference:  
The above table revealed that majority of both 70% of Out patients and 80% 
of In patients came under pitha kaalam, 30% of Out patients and 20% of In patients 
came under vatha kaalam.                                                                                                   
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4.2.3: Occupation 
Table 4.2.3: 
Distribution of Occupation 
 
S. 
No 
Occupation 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Employee 15 75% 11 55% 
2. Non Employee 3 15% 9 45% 
3. Student 2 10% 0 0% 
 
Figure 4.2.3: 
Distribution of occupation 
  
 
Inference: 
 Among  out patients, 75% were employees, 15% were Non Employees and 
10% were students. Among In patients 55% were Employees and 45% were Non 
Employees.
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4.2.4: Religion 
Table 4.2.4: 
Distribution of Religion 
S. 
No. 
Religion 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Hindu 16 80% 19 95% 
2. Christian 3 15% 1 5% 
3. Muslim 1 5% 0 0% 
 
Figure 4.2.4:  
Distribution of religion 
 
 
Inference: 
 Among  out patients 80% were Hindus, 15% were Chirstians and 5% were 
Muslims. Among  In patients 95% were Hindus and 5% were Christians. 
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4.2.5: Dietary Habits 
Table 4.2.5: 
Dietary Habits 
  
 
        
S. 
No. 
Diet 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Vegetarian 2 10% 1 5% 
2. 
Non –
Vegetarian(both) 
18 90% 19 95% 
 
Figure 4.2.5:  
Distribution of Dietary Habits 
 
 
 
Inference: 
                  This table revealed that majority of Out patients 90% and In patients 95%, 
were non vegetarian, compared to pure vegetarian. 
 
 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
OP IP
10%
5%
90%
95%
Vegetarian
Non -Vegetarian
64 
 
4.2.6: Dietary Time Habits: 
Table 4.2.6:  
Distribution Dietary Time Habits 
            
S. 
No. 
Diet 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. 
On regular 
time 
3 15% 4 20% 
2. 
On irregular 
time 
17 85% 16 80% 
 
Figure 4.2.6:  
Distribution of Dietary Time Habits 
 
 
 
Inference: 
 Among  20 out patients, 85% had Irregular Dietary time Habits. Among  In 
patients 80% had Irregular Dietary time Habits, compared to Regular Dietary time 
Habits. 
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4.2.7: Marital Status 
Table 4.2.7: 
Distribution of Marital Status 
            
S. 
No. 
Marital 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Married 16 80% 17 85% 
2. Unmarried 4 20% 3 15% 
 
Figure 4.2.7: 
Distribution of Marital Status 
 
 
 
Inference: 
         Among 20 Out patients 80% were married, 20% were unmarried.  
Among 20 Inpatients 85% were married, 15% were unmarried. 
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4.2.8: Personal Habits 
Table 4.2.8: 
Distribution of Personal Habits 
            
S. 
No. 
Habits 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Alcohol 0 0% 1 5% 
2. Smoking 0 0% 1 5% 
3. 
Alcohol with 
smoking 
2 10% 2 10% 
4. Non users 18 90% 16 80% 
 
Figure 4.2.8: 
Distribution of Personal Habits 
 
 
Inference: 
 This table revealed that majority of 90% of the out patients and 80% of the In 
patients  did not have bad habits, compared to other bad habits.  
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4.2.9: Nilam: 
Table 4.2.9: 
Distribution of Nilam 
S. 
No. 
Nilam 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Kurunji (Hill) 0 0% 0 0% 
2. Mullai (Forest) 0 0% 0 0% 
3. 
Marutham 
(Fertile) 
14 70% 15 75% 
4. 
Neithal 
(Coastal) 
6 30% 5 25% 
5. Pallai (Desert) 0 0% 0 0% 
 
Figure 4.2.9: 
Distribution of Nilam 
 
 
Inference: 
 Among out patients, 70% were from Marutham, 30% were from Neithal. 
Among In patients, 75% were from Marutham, 25% were from Neithal. 
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4.2.10: Kaalam (Season) 
Table 4.2.10: 
Distribution of Kaalam (Season) 
S. 
No. 
Kaalam 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Kaarkaalam 0 0% 1 5% 
2. Koothirkaalam 2 10% 2 10% 
3. Munpanikaalam 7 35% 4 20% 
4. Pinpanikaalam 2 10% 9 45% 
5. Ilavenil 5 25% 2 10% 
6. Mudhuvenil 4 20% 2 10% 
 
Figure 4.2.10: 
Distribution of Kaalam (season) 
 
Inference:  
 Among 20 out patients, 35% of patients came during Munpani kaalam and 
25% of patients came during Ilavenil kaalam & In patients, 45% of patients came 
during  Pinpani kaalam and 20% of patients came during Munpani kaalam. 
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4.2.11: Imporigal  
Table 4.2.11: 
Distribution of Imporigal 
  
 
        
S. 
No 
Imporigal 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Mei (Vishumbu) 1 5% 2 10% 
2. Sevi (Vali) 1 5% 1 5% 
3. Kan (Thee) 1 5% 1 5% 
4. Naaku (Appu) 4 20% 3 15% 
5. Mookku (Prithvi) 2 10% 2 10% 
 
Figure 4.2.11: 
Distribution of Imporigal 
 
 
 
Inference:  
          Among 20 Out patients, Naaku was affected in 20%, Mei and Mooku was   
equally affected in 10% & among 20 In patients, Naaku,Mei and Mooku was 
equally affected in 10%.  
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4.2.12: Kanmenthirium: 
 
Table 4.2.12: 
Distribution of Kanmenthirium 
S. 
No. 
Kanmenthirium 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Vai (Vishumbu) 0 0% 1 5% 
2. Kal (Vali) 3 15% 6 30% 
3. Kai (Thee) 5 25% 6 30% 
4. Eruvai (Appu) 11 55% 7 35% 
5. Karuvai (Prithvi) 3 15% 3 15% 
 
Figure 4.2.12: 
Distribution of Kanmenthirum 
 
 
Inference:          
          Among 20 Out patients, Eruvaai was affected in 55%, Kai was affected in 
25% and Karuvaai was affected in 15% & among 20 In patients, Eruvaai was 
affected in 55%, Kai was affected in 25% and Karuvaai was affected in 15%. 
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4.2.13: Uyir Thathukal  
Table 4.2.13.1: 
Distribution of Vatham 
S. 
No 
Vatham 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Pranan(vali) 3 15% 4 10% 
2. Abanan(Thee) 17 85% 20 100% 
3. Viyanan(visumbu) 14 70% 13 65% 
4. Uthanan(prithvi) 15 75% 17 85% 
5. Samanan(appu) 20 100% 20 100% 
6. Nagan 2 10% 4 20% 
7. Koorman 2 10% 5 25% 
8. Kirugaran 16 80% 15 75% 
9. Thevathathan 10 50% 12 60% 
10. Thanajeyan 0 0% 0 0% 
 
Inference: 
       Among 20 Out patients and 20 In patients Samanan were affected in 100%, 
Abanan was affected in 100% of In patients, 85% of Out patients. Whereas Uthanan 
was affected in 85% of In patients and 75% of Out patients, Kirukaran was affected in 
80% of Out patients and 75% of In patients, Viyanan was affected in 70% of Out 
patients and 65% of In patients, Thevathathan was affected in 50% of Out patients 
60% of In patients compared to other vayus. 
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Figure 4.2.13.1:  
Distribution of Vatham 
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4.2.13.2: Pitham 
Table 4.2.13.2: 
Distribution of Pitham 
S. 
No 
Pitham 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Analapitham 16 80% 15 75% 
2. Ranjagapitham 8 40% 12 60% 
3. Sathagapitham 13 65% 10 50% 
4. Prasagapitham 0 0% 2 10% 
5. Alosagapitham 0 0% 1 5% 
 
Figure 4.2.13.2: 
Distribution of Pitham 
 
Inference:  
 This table revealed that among 20 Out patients, Analapitham was affected in 
80%, Sathagapitham was affected in 65%, Ranjagapitham was affected in 40%. 
Among 20 In patients, in Analapitham was affected in 75%, Ranjagapitham was 
affected in 60%, Sathagapitham was affected in 50%, Prasagapitham was affected in 
10% & Alosagapitham was affected in 5%. 
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 4.2.13.3: Kabam 
Table 4.2.13.3: 
Distribution of Kabam 
S. 
No 
Kabam 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Avalambagam 10 50% 10 50% 
2. Kilethagam 3 15% 5 25% 
3. Pothagam 4 20% 3 15% 
4. Tharpagam 0 0% 0 0% 
5. Santhigam 5 25% 7 35% 
 
Figure 4.2.13.3: 
Distribution of Kabam 
 
 
Inference: 
          This table revealed that majority 50% of out patients and In patients, 
Avalambagam was affected, In 25% of Out patients and 35% of In patients Santhigam 
was affected, In 15% of Out patients and 25% of In patients Kilethagam was affected 
& In 20% of Out patients and 15% of In patients Pothagam was affected. 
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4.2.14: Ezhu Udarkattukal 
Table 4.2.14.1: 
Ezhu Udarkattukal (Increased) 
S. 
No. 
Ezhu Udarkattukal 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Saaram increased 15 75% 17 85% 
2. Seneer increased 15 75% 14 70% 
3. Oon increased 0 0% 0 0% 
4. Kozhuppu increased 1 5% 0 0% 
5. Enbu increased 0 0% 0 0% 
6. Moolai increased 1 5% 0 0% 
7. 
Sukkilam / Suronitham 
increased 
0 0% 1 5% 
Figure 4.2.14.1: 
Ezhu Udarkattukal (Increased) 
 
 
Inference: 
                This table revealed that Saaram was increased in 75% of Out patients and 
85% of In patients & Seneer was increased in 75% of Out patients and 70% of In 
patients. 
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4.2.14.2: Ezhu Udarkattukal (Decreased) 
Table 4.2.14.2: 
Ezhu Udarkattukal (Decreased) 
S. 
No. 
Ezhu Udarkattukal 
Out patients In patients 
No. 
of 
Cases 
Percentage 
No. 
of 
Cases 
Percentage 
1. Saaram decreased 5 25% 6 30% 
2. Seneer decreased 6 30% 5 25% 
3. Oon decreased 5 25% 7 35% 
4. Kozhuppu decreased 7 35% 5 25% 
5. Enbu decreased 5 25% 7 35% 
6. Moolai decreased 6 30% 4 20% 
7. Sukkilam / Suronitham decreased 6 30% 4 20% 
 
Figure 4.2.14.2: 
Ezhu Udarkattukal (Decreased) 
 
Inference:  
 Among Out patients Saram was decreased in 25%, Seneer was decreased in 
30%, Oon was decreased in 25%, Kozhuppu was decreased in 35%, Enbu was 
decreased in 25%, Moolai was decreased in 30% & Sukkilam/Suronitham was 
decreased in 30%. Whereas In patients Saram was decreased in 30%, Seneer was 
decreased in 25%, Oon was decreased in 35%, Kozhuppu was decreased in 25%, 
Enbu was decreased in 35%, Moolai was decreased in 20% & Sukkilam/Suronitham 
was decreased in 20%. 
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4.2.15: Kosangal 
Table 4.2.15: 
Distribution of Kosangal 
S. 
No. 
Kosangal 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Annamayakosam 20 100% 20 100% 
2. Pranamayakosam 15 75% 16 80% 
3. Manomayakosam 1 5% 2 10% 
4. Vignamayakosam 0 0% 2 0% 
5. Anandamayakosam 12 60% 13 65% 
 
Figure 4.2.15: 
Distribution of Kosangal 
 
Inference: 
                 This table revealed that Annamayakosam was affected in all of the Out 
patients and In patients, Pranamayakosam was affected in 75% of Out patients and 
80% of In patients, Ananthamayakosam was affected in 60% of Out patients and 65% 
of In patients & Pranamayakosam was affected in few cases. 
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4.2.16.1: Envagai thervugal - Naadi 
Table 4.2.16.1: 
Distribution of Naadi 
S. 
No. 
Naadi 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Vaatha naadi (V) 3 15% 4 20% 
2. Pitha Naadi (P) 1 5% 1 5% 
3. Kaba naadi (K) 0 0% 0 0% 
4. Vaatha pitha Naadi(VP) 3 15% 4 20% 
5. Vaatha kaba naadi(VK) 0 0% 0 0% 
6. PithaVaatha Naadi(PV) 12 60% 11 55% 
7. Pitha Kaba Naadi(PK) 0 0% 0 0% 
8. Kaba Vaatha naadi(KV) 2 10% 0 0% 
9. Kaba Pitha Naadi(KP) 0 0% 0 0% 
10. Mukkutram Naadi (M) 0 0% 0 0% 
Figure 4.2.16.1: 
Distribution of Naadi 
 
Inference: 
          This table revealed that 60% of Out patients and 55% of In patients were with 
Pitha vaatha naadi. 20% of In patients were with Vatha naadi, 20% of In patients 
were with Vathapitha naadi, 15% of Out patients were with Vatha naadi and 15% of 
Out patients were with Vathapitha naadi. 
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4.2.16.2: Sparism, Naa, Niram, Mozhi, Vizhi, Malam 
Table 4.2.16.2: 
Distribution of Sparism, Naa, Niram, Mozhi, Vizhi,Malam 
S. 
No.  
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Sparism 5 25% 6 30% 
2. Naa 7 35% 4 20% 
3. Niram 3 15% 8 40% 
4. Mozhi 6 30% 7 35% 
5. Vizhi 4 20% 3 15% 
6. Malam 10 50% 12 60% 
 
Figure 4.2.16.2: 
Distribution of Sparism, Naa, Niram, Mozhi, Vizhi, Malam 
 
 
Inference: 
            Among 40 patients Malam was affected in 50% of Out patients 
 and 60% of In patients, Sparism was affected in 25% of Outpatients and 30% of  
In patients, Naa was affected in 35% of Out patients and 20% of In patients, Niram 
was affected in 15% of Out patients and 40% of In patients, Mozhi was affected in 
30% of Out patients & 35% of In patients & Vizhi was affected in 20% of Out patients 
and 15% of In patients. 
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4.2.16.3: Neerkuri 
4.2.16.3.1: Neer -Niram 
Table 4.2.16.3.1: 
Distribution of Neer- Niram 
S. 
No. 
Niram 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Manjal neer 15 75% 16 70% 
2. Patchai Neer 0 0% 0 0% 
3. Karuppu Neer 0 0% 0 0% 
4. Vellai Neer 5 25% 3 15% 
5. Sivappu Neer 0 0% 1 5% 
 
Figure 4.2.16.3.1: 
Distribution of Neer Niram 
 
Inference: 
  Among 40 patients 75% of Outpatients and 70% of In patients were shown 
Manjal neer, Vellai neer was shown in 25% of Out patients and 15% of In 
patients. Few cases were shown Sivappu neer. 
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4.2.16.3.2: Neer-Manam, Edai, Nurai, Enjal 
 
Table 4.2.16.3.2: 
Distribution of Manam,Edai,Nurai,Enjal 
 
S. 
No. 
Neer 
Out patients In patients 
No.of 
Cases 
Percentage 
No.of 
Cases 
Percentage 
1. Manam 1 5% 1 5% 
2. Edai 0 0% 1 5% 
3. Nurai 7 35% 4 20% 
4. Enjal 0 0% 1 5% 
 
Figure 4.2.16.3.2: 
Distribution of Manam, Edai, Nurai, Enjal 
 
Inference: 
 Among 40 patients Manam was affected in 5% of Out patients and In patients, 
Edai was affected in 5% of In patients. Nurai was affected in 35% of Out patients and 
20% of In patients.  
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4.2.17: Neikuri 
Table 4.2.17: 
Distribution of Neikuri 
S.No.  
Neikuri Frequency Percentage 
1. 
Sathiya Neikuri 38 95.00% 
2. 
Asathiya Neikuri 2 5.00% 
3. 
Total 40 100.00% 
 
Figure 4.2.17: 
Distribution of Neikuri 
 
 
Inference:  
 Among 40 patients 95.00% were showing Sathiya Neikuri and 5.00% were 
showing  Asathiya Neikuri. 
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4.2.18: Habits of controlling 14 Vegangal 
 Table 4.2.18: 
Distribution of 14 Vegangal 
S. 
No. 14 Vegangal 
Out patients In patients 
No. of Cases Percentage No. of Cases Percentage 
1. Abanavayu 17 85% 14 70% 
2. Appetite 17 85% 14 70% 
3. Thirst 13 65% 13 65% 
4. Tears 11 55% 12 60% 
5. Yawning 9 45% 13 65% 
6. Fatigue 11 55% 12 60% 
 
Table 4.2.18:   
Distribution of 14 vegangal 
 
 
Inference: 
 Among 20 Out patients 85% were controlled the Abanavayu and Appetite, 
65% were controlled the Thirst, 55% were controlled the Tears & Fatigue, 45% were 
controlled the Yawning. Among 20 In patients 70% were controlled the Abanavayu 
and Appetite, 65% were controlled the Thirst & Yawning, 60% were controlled the 
Tears & Fatigue. 
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4.2.19: Udarthee 
Table 4.2.19:  
Distribution of Udarthee 
S. 
No. 
Udarthee 
Out patients In patients 
No. Of cases Percentage No. Of cases Percentage 
1. Samanakkini 2 10% 2 15% 
2. Theekshanakkini 1 5% 1 5% 
3. Vishamakini 6 30% 5 25% 
4. Mandhakini 11 55% 12 60% 
 
Figure 4.2.19:  
Distribution of Udarthee 
 
 
 
Inference: 
 Among 20 Out patients, 10% of patients were with Samanakkini, 5% of 
patients were with Theekshanakkini, 55% of patients were with Mandhakkini and 30% 
of patients were with Vishamakkini. Among 20 In patients, 15% of patients were with 
Samanakkini, 5% of patients were with Theekshanakkini, 60% of patients were with 
Mandhakkini and 25% of patients were with Vishamakkini. 
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4.2.20: Thegi Ilakkanam 
Table 4.2.20:  
Distribution of Thegi Ilakkanam 
 
S. 
No 
Naadi 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1. Vaatha Thegi (VT) 3 15% 3 15% 
2. Pitha Thegi (PT) 1 5% 2 10% 
3. Kaba Thegi (KT) 0 0% 0 0% 
4. Vaathapitha Thegi (VPT) 5 25% 5 25% 
5. Vaathakaba Thegi (VKT) 1 5% 1 5% 
6. PithaVaatha Thegi (PVT) 8 40% 7 35% 
7. Pitha Kaba Thegi (PKT) 1 5% 1 5% 
8. KabaVaathaThegi (KVT) 0 0% 1 5% 
9. Kaba Pitha Thegi (KPT) 1 5% 0 0% 
10. Mukkutra Thegi (MT) 0 0% 0 0% 
 
 
Inference: 
 This table revealed that, Out patients 15% and In patients 15% were Vaatha 
Thegi. Out patients 5% & In patients 10% were Pitha Thegi. 25% Out patients and 
25% In patients were Vaatha Pitha Thegi. 5% Out patients and 5% In patients were 
Vaatha Kaba Thegi. 40% Out patients & 35% In patients were Pitha Vaatha Thegi. 
5% Out patients & 5% Inpatients were Pitha Kaba Thegi. 5% Inpatients were Kaba 
Vaatha Thegi. 5% Out patients were Kaba Pitha Thegi. 
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Figure 4.2.20:  
Distribution of Thegi Ilakkanam 
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4.2.21: Gunam 
Table 4.2.21: 
Distribution of Gunam 
S. 
No. 
Gunam 
Out patients In patients 
No. of 
Cases 
Percentage 
No. of 
Cases 
Percentage 
1 Sathuvagunam 1 5% 2 10% 
2 Rajogunam 16 80% 14 70% 
3 Thamogunam 3 15% 4 20% 
 
Figure 4.2.21: 
Distribution of Gunam 
 
 
Inference:  
            Among Out patients, 80% were with Rajogunam, 15% were with 
Thamogunam and 5% were with Sathuvagunam. 
           Among In patients, 70% were with Rajogunam, 10% were with Sathuvagunam 
and 20% were with Thamogunam. 
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4.2.22: Manikadainool 
Table 4.2.22: 
Distribution of Manikadainool 
S. 
No. 
Virarkadai Frequency Percentage 
1. 9 ¼  1 2.50% 
2. 9 ½  3 7.50% 
3. 9 ¾  5 12.50% 
4. 10 31 77.50% 
5. Total 40 100.00% 
 
Figure 4.2.22: 
Distribution of Manikadainool 
 
 
 
Inference: 
Among 40 patients 2.5% were in 9¼ Virarkadai, 7.5% were in 9½ Virarkadai, 
12.5% were in 9¾ Virarkadai and 77.5% were in 10 Virarkadai. 
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4.2.23: Clinical symptoms before (Visit 1) and after (Visit 5) treatment 
Table 4.2.23: 
Distribution of Clinical symptoms before (Visit 1) and after (Visit 5) treatment 
 
Symptoms 
 
No. Of 
Cases 
Percentage 
Burning sensation in upper abdomen Visit 1 39 97.5 
Visit 5 1 2.5 
Nausea Visit 1 33 82.5 
Visit 5 0 0 
Water brush Visit 1 29 72.5 
Visit 5 3 7.5 
Head ache Visit 1 19 47.5 
Visit 5 1 2.5 
Flatulence Visit 1 26 65 
Visit 5 1 2.5 
Dizziness Visit 1 15 37.5 
Visit 5 1 2.5 
Ex. Sweating Visit 1 15 37.5 
Visit 5 2 5 
Loss.of weight Visit 1 17 42.5 
Visit 5 3 7.5 
Loss.of appetite Visit 1 29 72.5 
Visit 5 0 0 
Neuritic pain Visit 1 12 30 
Visit 5 2 5 
Cough Visit 1 13 32.5 
Visit 5 1 2.5 
 
 All the 40 patients showed that the significant prognosis in Visit 5 based on 
the evaluation of symptoms. 
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Figure 4.2.23: 
Distribution of Clinical symptoms before (visit 1) and after treatment (visit 5) 
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4.2.24: Grade before and after treatment 
Table 4.2.24: 
Distribution of Grade (Visit 1- Visit 5) (BT-AT) 
S. 
No.  
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
1. Visit 1 
  
7 23 10 
2. Visit 2 
 
9 23 8 
 
3. Visit 3 5 11 18 6 
 
4. Visit 4 16 12 8 4 
 
5. Visit 5 28 6 6 
  
 
Inference: 
 In Visit 1 Grade 2 was in 7 patients, Grade 3 was in 23 patients, Grade 4 was 
in 10 patients. In Visit 2 Grade was 1 in 9 patients, Grade 2 was in 23 patients, Grade 
3 was in 8 patients. In Visit 3 Grade 0 was in 5 patients, Grade 1 was in 11 patients, 
Grade 2 was in 18 patients, and Grade 3 was in 6 patients. In Visit 4 Grade 0 was in 
16 patients, Grade 1 was in 12 patients, Grade 2 was in 8 patients, and Grade 3 was in 
4 patients. In Visit 5 Grade 0 was in 28 patients, Grade 1 was in 6 patients, Grade 2 
was in 6 patients. 
Figure 4.2.24: Distribution of Grade (Visit 1- Visit 5) (BT-AT) 
 
Grade: 0 - Clinically cured - CAS=0-5; Grade: 1 - Clinically well improved-CAS=6-10; Grade: 2 
- Marginal clinical improvement - CAS=11-40; Grade: 3 - Mild clinical improvement - CAS=41-
70; Grade: 4 - No changes clinically - CAS ≥70 
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4.2.25: Difference analysis for prognosis 
Table 4.2.25: Significance between CAS and outcome (Visit1& Visit5) 
 
No. Mean 
Std. 
Deviation 
t value P value 
Visit 1 40 3.07 0.656 
33.861 <0.0001 
visit 5 40 0.45 0.749 
 
(Paired “t” Test) 
Depending upon P value the prognosis is Significant. 
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CHAPTER- V 
DISCUSSION 
 
5.1 The recruited patient’s data shows 
 
1. More prevalence in Male. The Male to Female ratio is 1.6:1. 
2. Most of patients belong to Pitha Kaalam (34-66yrs). 
3. Commonly affected were Employees (65%) and those having irregular dietary 
time habits. 
4. Mostly Marutham nilam people were affected in Gunma noi(72.5% )  
5. More prevalence in Pinpani Kaalam, because of Kabam (Thannilai Valarchi) 
which leads to altered Pitham. 
6. In Imporigal, Naaku was affected in 17.5%, which may be due to affected 
taste perception. 
7. In Kanmendhiriyam, Eruvai was affected in 45%. Most of them had loose 
stool with increased flatus. 
8. Uyir Thathukkal affection status were as follows;  
i. Vatham – 100% Samanan (due to digestive disturbances) affected 
followed by Abanan 92.5% (presence of loose stools, flatus) & then 
by Udhanan 80% (stagnation of digestive matters causing  perverted 
appetite)  
ii. Pitham – Anarpitham (due to digestive disturbances) affected in 
77.5% 
iii. Kabam – Avalambagam (due to imbalance in other 4 Iyam‟s) 
affected in 50%, followed by Santhigam 30% (Restriction in 
movement of joints). 
9. In Udar Thathukkal,  
      Table 4.2.14.1 & Table 4.2.14.2 showed, 
i. Saaram increased up to 80% and followed by Seneer 72.5%,  
ii. Remaining 5 thathus decreased (this may be due to 
disturbances in Abanan & Samanan). 
10. In Kosangal, Annamayakosam affected in all patients 100%, followed by 
Pranamaya Kosam (77.5%) & Aanandhamaya Kosam (62.5%). 
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11. Envagai Thervu  
i. Naadi – Pitha Vaatha naadi 57.5%, Vaatha Pitha and Vatha naadi 
17.5% were recorded. 
ii. Malam 55%, Mozhi 32.5% was affected. Remaining was not affected 
significantly. 
iii. Neer  – Niram – Manjal 72.5% 
Nurai – 27.5%. 
12. Saathiya Neikuri 95%, Asaathiya Neikuri 5% was recorded. 
13. Among 14 Vegangal, Abanavayu & Appetite were voluntarily controlled by 
77.5% patients. 
14. Udarthee was Mandhakkini in 57.5% & Vishamakkini in 27.5%. 
15. Erigunmam was Common in Pitha Vatha thegi 35%. 
16. Common in Rajo Gunam 77.5%, followed by Thamo Gunam 17.5%. 
17. In Manikadainool, 10 Virarkadai in 77.5%. 
18. Grades were gradually decreased in visit 5. 
19. Statistically significant (p <0.0001) between Visit 1 & Visit 5 using „Paired t 
test‟. 
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CHAPTER- VI 
 THE SUMMARY & CONCLUSION 
(Summation) 
The 40 patients with CAS Grade ≤ 2 were allocated to treatment with 
Vellarugu Chooranam 2 gm Bd with warm water for 30 days. No adverse reaction 
was found. Males also had more or less equal preponderance with females. Pitha 
Kaalam (34 -66yrs) had more prevalence. Due to modernisation and industrialitation, 
prevalence of Eri Gunmam has been emerging in Marutham too. The increased 
Saaram and Seneer doesn‟t get distributed to other Udar kattugal may be due to 
disturbed functioning of Abanan & Samanan. Annamaya Kosam commonly affected. 
Rajo Gunam has high prevalence followed by Thammo Gunam. Mandhakkini may be 
due to voluntarily controlling of reflexes (14 vegangal noted in all patients), which 
may be the risk factor for devolping Eri Gunmam. Vitation of Pitham resulted in 
disturbed Vaatham was noted. For the management, the Vellarugu Chooranam having 
the taste of Kaippu (Valli + Aakaayam) works well. The Preclinical data add an 
account for anti ulcer activity. The study showed the clinical efficacy (Grade, p 
value<0.0001) of Vellarugu Chooranam is clinically significant, which was evaluated 
by trial. This study gives immense data for treating and preventing the Eri Gunmam & 
shows new arena for further research.  
 
From my dissertation work, Eri Gunmam may be defined as a disease in  Pitha 
sthanam due to altered Vaatham & Pitham (Thee) which in turn may be due to 
Controlled reflexes(Vatham).On the basis of Suvai, Vellarugu Chooranam the being a 
combination Kaippu, leads to good prognosis. 
 
From the Preclinical studies, 
1. Biochemical studies shows the presence of 
 Calcium, Sulphate, Chloride, Starch 
 Ferrous iron, unsaturated compound, Amino acid. 
2.  Phytochemical studies show the presence of Flavanoids, alkaloids,    
phytosterols, tannins, carbohydrates and glycosides, Lignin, Saponin. 
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3. Anti- Microbial activity, 
 Showed that Vellarugu Chooranam has the anti microbial 
activity against staphylococcus aureus, bacillus Subtilis, klebsilla pneumonia 
and E-coli. 
4. The Pharmacological study has confirmed the significant effect of Anti-ulcer 
activity. 
5. No acute and subacute toxicity were observed in any other group of animals, 
at the maximum recomputed dose level of 2gm. Vellarugu chooranam has not 
produced liver and other organ damage. 
6. Based on Clinical Assessment Score, Vellarugu Chooranam was found to be 
highly effective for Eri Gunmam. 
 
 
CASE SHEET OF 20 IN PARENTS TREATED FOR ERI GUNMAM 
S.NO IPD.NO NAME AGE SEX DOA DOD NO.OF DAYS 
TREATED 
RESULT 
IP OP 
1.  2015 NAGA ARJUN 27 M 6/8/2018 20/8/2018 15 15 GOOD 
2.  2049 PARI POORANAM 43 F 10/8/2018 20/9/2018 42 - GOOD 
3.  2541 CHANDHIRA 58 F 8/10/2018 8/11/2018 30 - GOOD 
4.  3022 VELLATHAI 60 F 10/12/2018 31/12/2018 22 8 MODERATE 
5.  3065 ESSAKKI MUTHU 29 M 13/12/2018 11/01/2019 30 - GOOD 
6.  3101 SELVI 56 F 18/12/2018 17/01/2019 30       - GOOD 
7.  57 SANTHANA 
MARIMUTHU 
42 M 14/01/2019 12/02/2019 30 - GOOD 
8.  94 SWARNAM 60 F 19/01/2019 08/02/2019 21 9 MODERATE 
9.  363 PETCHIYAMMAL 55 F 14/02/2019 13/03/2019 30 - GOOD 
10.  400 KALANGIUM 60 M 18/02/2019 19/03/2019 30 - GOOD 
11.  412 PANDIYAN 58 M 19/02/2019 20/03/2019 30 - GOOD 
12.  500 RAJASEKAR 34 M 26/02/2019 21/03/2019 24 6 MODERATE 
13.  557 VELTHAI 48 F 04/03/2019 02/04/2019 30 - GOOD 
14.  614 TAMILSELVI 55 F 09/03/2019 07/04/2019 30 - GOOD 
15.  626 MADATHI 51 F 11/03/2019 10/04/2019 30 - GOOD 
16.  664 VAIKUNDATHAMMAL 60 F 11/03/2019 09/04/2019 30 - MODERATE 
17.  841 DURAIPANDI 53 M 01/04/2019 25/04/2019 25 5 GOOD 
18.  894 KUMAR 48 M 08/04/2019 30/04/2019 23 7 GOOD 
19.  997 RAMAMOORTHI 49 M 22/04/2019 02/06/2019 42 - GOOD 
20.  1149 GANESAN 42 M 06/05/2019 04/06/2019 30 - GOOD 
 
CASE SHEET OF 20 OUT PATIENTS TREATED FOR ERI GUNMAM 
S.NO OP.NO NAME AGE SEX 
STARTING OF 
TREATMENT 
END 
OFTREATMENT 
NO OF DAYS 
TREATED 
RESULT 
1. 31676 SIVA 30 M 05/04/2018 04/05/2018 30 DAYS GOOD 
2. 40162 NIVEDHA 20 F 25/04/2018 24/05/2018 30 DAYS     GOOD 
3. 43290 JEYA CHANDRAN 33 M 16/05/2018 14/06/2018 30 DAYS GOOD 
4. 43671 GANESAN 48 M 17/05/2018 15/06/2018 30 DAYS GOOD 
5. 44600 GANESAN 43 M 21/05/2018 19/06/2018 30 DAYS GOOD 
6. 44882 GANESH RAJA 40 M 22/05/2018 20/06/2018 30 DAYS GOOD 
7. 56603 AATHIYAPPAN 45 M 06/07/2018 04/08/2018 30 DAYS GOOD 
8. 57663 ISMAYIL 42 M 10/07/2018 08/08/2018 30 DAYS MODERATE 
9. 61627 
BABU 
LAKSHMANAN 
48 M 24/07/2018 22/08/2018 
30 DAYS MODERATE 
10. 63103 ESSAKI MUTHU 29 M 30/07/2018 28/08/2018 30 DAYS GOOD 
11. 102566 CHITHIRAI PANDI 28 M 11/12/2018 09/01/2019 30 DAYS GOOD 
12. 102876 SATHISH KUMAR 49 M 12/12/2018 10/01/2019 30 DAYS GOOD 
13. 103905 KRISHNA KUMAR 35 M 15/12/2018 13/01/2019 30 DAYS GOOD 
14. 931 SWARNAM 44 F 03/01/2019 01/02/2019 30 DAYS GOOD 
15. 3296 MAHESH 42 M 07/01/2019 05/01/2019 30 DAYS GOOD 
16. 4977 EPSHEEBA 23 F 11/01/2019 09/01/2019 30 DAYS GOOD 
17. 14546 MARIAPPAN 50 F 08/02/2019 09/03/2019 30 DAYS GOOD 
18. 15332 ANTONY RAJ 47 M 11/02/2019 12/03/2019 30 DAYS MODERATE 
19. 15507 SARASWATHI 50 F 11/02/2019 12/03/2019 30 DAYS GOOD 
20. 17397 
SILUVAI 
THANGARAJ 
45 M 16/02/2019 17/03/2019 
30 DAYS GOOD 
 
SI. 
 
NO 
IP 
 
 NO 
                    HAEMATOLOGICAL REPORT 
 
                    URINE   ANALYSIS 
BEFORE TREATMENT  AFTER TREATMENT BEFORE TREATMENT  AFTER TREATMENT 
TC 
cells/c
u.mm 
DC  
ESR 
(1hr) 
Hb 
gms   
% 
TC 
cells/c
u.mm 
DC ESR 
(1hr) 
Hb 
gms   
% 
Alb Sug Dep – 
Epi cells/ 
Pus cells 
Alb Sug Dep – 
Epi cells/ 
Pus cells 
P
% 
L
% 
E
% 
P 
% 
L
% 
E 
% 
1. 
2015 
6000 58 39 3 4 13.5 6500 59 39 2 4 11.1 NIL NIL NAD NIL NIL NAD 
2. 
2049 
7000 55 43 2 6 12.4 7100 57 40 3 7 12.9 NIL NIL NAD NIL NIL NAD 
3. 2541 8300 53 42 5 10 11.4 7500 59 39 2 9 12 NIL NIL NAD NAD NIL NAD 
4. 3022 7500 56 39 5 9 11.6 7600 57 40 3 7 11.9 NIL NIL NAD NIL NIL NAD 
5. 3065 9300 59 36 5 8 11.1 8800 60 35 5 6 11.0 NIL NIL NAD NIL NIL NAD 
6. 3101 7400 60 37 3 9 13.5 7300 62 33 5 12 11.8 NIL NIL NAD NIL NIL NAD 
7. 57 7400 58 40 2 10 12.0 7000 60 38 2 10 12.8 NIL NIL NAD NAD NIL NIL 
8. 94 7900 57 38 5 6 11.1 7500 64 33 3 11 9.5 NIL NIL NAD NIL NIL NAD 
9. 363 8500 63 33 4 9 11.4 8700 57 40 3 10 11.3 NIL NIL NAD NIL NIL NAD 
10. 400 7800 58 36 4 8 12.8 7900 58 40 2 6 13.2 NIL NIL NAD NIL NIL NAD 
11 412 7300 56 38 6 5 10.5 7400 55 41 4 4 11.8 NIL NIL 2-3epi .cells NIL NIL NAD 
12. 
500 
7400 60 37 3 5 12.7 7700 63 35 2 19 12.6 NIL NIL Few pus cells NIL NIL NAD 
13. 
557 
7600 56 42 2 6 11 7800 60 38 2 6 11.7 NIL NIL NAD NIL NIL NAD 
14 
614 
7300 57 40 3 4 12.1 7300 60 36 4 5 13.0 NIL NIL NAD NIL NIL NAD 
15. 
626 
6000 58 40 2 5 13.8 6400 65 43 2 9 14.3 NIL NIL NAD NIL NIL NAD 
16. 
664 
8300 66 31 3 4 14.3 8200 64 34 2 7 13.9 NIL NIL Few pus cells NIL NIL NAD 
17. 
841 
8500 62 31 7 8 9.7 8300 61 35 4 6 10.6 NIL NIL NAD NIL NIL NAD 
18. 
894 
6800 60 36 4 5 10.9 6400 62 36 2 7 12.8 NIL NIL NAD NIL NIL NAD 
19. 
997 
8900 63 30 8 6 10.4 8600 59 38 3 5 11.4 NIL NIL NAD NIL NIL NAD 
20. 
1149 
7800 62 34 4 6 11.4 7600 67 26 2 4 11.2 NIL NIL 1-2 puscells NIL NIL NAD 
LABORATORY INVESTIGATIONS (IP PATIENTS ) 
 
 SI. 
N
O 
OP 
 
 NO 
                    HAEMATOLOGICAL REPORT 
 
                    URINE   ANALYSIS 
BEFORE TREATMENT  AFTER TREATMENT BEFORE TREATMENT  AFTER TREATMENT 
TC 
cells/c
u.mm 
DC  
ESR 
(1hr) 
Hb 
gms   
% 
TC 
cells/c
u.mm 
DC ES
R 
(1h
r) 
Hb 
gms   
% 
Alb Sug Dep – 
Epi cells/ 
Pus cells 
Alb Sug Dep – 
Epi cells/ 
Pus cells 
P
% 
L
% 
E
% 
P% L% E% 
1. 31676 6200 56 42 2 20 10.7 6500 50 46 4 15 11.1 NIL NIL NAD NIL NIL NAD 
2. 40162 7300 69 28 3 13 12.4 7100 67 30 2 8 12.9 NIL NIL NAD NIL NIL NAD 
3. 43290 8600 65 31 4 14 10.5 7500 69 28 3 10 10.9 NIL NIL NAD NAD NIL NAD 
4. 43671 7200 66 31 3 08 10.2 9600 71 27 2 07 11.9 NIL NIL NAD NIL NIL NAD 
5. 44600 7900 69 28 3 12 11.1 9500 72 25 5 11 12 NIL NIL NAD NIL NIL NAD 
6. 44882 7400 67 30 3 08 13.5 7300 70 23 5 10 13.8 NIL NIL NAD NIL NIL NAD 
7. 56603 8100 67 30 3 15 12.3 7300 60 38 2 08 12.8 NIL NIL 1-2 pus 
cells 
NAD NIL NAD 
8. 57663 6400 55 41 4 32 12.4 6400 56 30 4 25 13 NIL NIL NAD NIL NIL NAD 
9. 61627 7500 66 31 3 10 11 8700 66 29 3 10 11.3 NIL NIL NAD NIL NIL NAD 
10. 63103 7700 59 35 6 11 12.8 7900 60 40 2 06 13.2 NIL NIL NAD NIL NIL NAD 
11. 102566 8300 66 32 2 09 10.5 7400 65 23 4 12 11.8 NIL NIL 2-3 
epi .cells 
NIL NIL NAD 
12. 102876 9200 68 30 2 13 12.7 9700 73 37 2 19 12.6 NIL NIL Few 
pus cells 
NIL NIL NAD 
13. 103905 7800 60 36 4 21 12 7800 61 31 2 17 13 NIL NIL NAD NIL NIL NAD 
14. 931 8300 67 30 3 17 12.1 7800 60 36 4 15 13.0 NIL NIL NAD NIL NIL NAD 
15. 3296 6000 55 42 3 15 12.9 6400 55 43 2 09 14.0 NIL NIL NAD NIL NIL NAD 
16. 4977 7600 66 32 2 10 12.3 8500 64 33 2 07 13 NIL NIL Few 
pus cells 
NIL NIL NAD 
17. 14546 7100 60 35 5 06 9.7 8300 60 35 4 07 10.3 NIL NIL NAD NIL NIL NAD 
18. 15332 6800 62 36 2 13 10.9 5400 67 24 3 08 12.8 NIL NIL NAD NIL NIL NAD 
19. 15507 7900 64 34 2 12 10.4 8600 59 27 3 13 11.4 NIL NIL NAD NIL NIL NAD 
20. 
17397 
6800 67 29 4 06 11.4 7600 67 26 2 06 11.2 NIL NIL 
1-2  
puscells NIL NIL NAD 
LABORATORY INVESTIGATIONS (OP PATIENTS ) 
 
 SI 
NO 
OP 
NO 
Before treatment After treatment 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholestrol 
Serum 
creatinine 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
creatinine 
1. 31676 110 20 200 0.5 112 22 190 0.4 
2. 40162 90 25 182 0.6 102 23 170 0.5 
3. 43290 112 26 220 0.8 108 24 180 0.5 
4. 43671 100 25 169 0.6 118 27 142 0.6 
5. 44600 108 26 202 0.5 115 28 190 0.6 
6. 44882 120 27 167 0.9 120 25 160 0.8 
7. 56603 115 27 186 0.7 118 23 170 0.5 
8. 57663 102 28 195 0.7 114 27 190 0.8 
9. 61627 105 24 180 0.5 109 25 160 0.7 
10. 63103 95 26 145 0.8 108 24 150 0.7 
11. 102566 130 24 187 0.8 120 24 196 0.8 
12. 102876 115 28 180 0.9 107 26 168 0.8 
13. 103905 113 26 167 0.7 120 25 156 0.6 
14. 931 99 30 196 1.0 115 27 180 0.9 
15. 3296 118 31 168 0.8 110 30 155 0.6 
16. 4977 99 18 180 1.0 100 20 155 0.8 
17. 14546 114 19 175 0.7 112 21 169 0.6 
18. 15332 109 21 156 0.6 106 23 146 0.6 
19. 15507 116 17 170 0.8 110 22 178 0.5 
20. 17397 102 22 190 0.9 100 25 174 0.7 
 
 
 
LABORATORY INVESTIGATIONS (OP PATIENTS) 
 
  
SI 
NO 
IP 
NO 
Before treatment After treatment 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholestrol 
Serum 
creatinine 
Blood 
sugar(R) 
Blood 
Urea 
Serum 
cholesterol 
Serum 
creatinine 
1. 2015 109 25 208 0.5 112 24 196 0.4 
2. 2049 100 20 168 0.6 102 23 160 0.5 
3. 2541 110 27 226 0.8 108 20 170 0.5 
4. 3022 120 25 169 0.6 118 28 143 0.6 
5. 3065 111 28 200 0.5 115 29 187 0.6 
6. 3101 120 27 157 0.9 117 27 130 0.8 
7. 57 109 27 169 0.7 102 24 161 0.5 
8. 94 110 27 186 0.7 109 28 179 0.8 
9. 363 120 24 187 0.5 103 25 156 0.7 
10. 400 98 24 131 1.0 100 26 124 0.8 
11. 412 120 26 187 0.9 113 24 196 1.0 
12. 500 113 28 170 0.8 107 26 148 0.9 
13. 557 104 26 167 0.5 120 25 156 0.7 
14. 614 99 24 196 1.0 100 20 180 0.9 
15. 626 118 32 168 0.8 120 34 155 0.6 
16. 664 95 15 166 1.0 112 23 112 0.9 
17. 841 110 16 171 0.6 108 21 120 0.5 
18. 894 108 25 148 0.6 106 23 140 0.6 
19. 997 119 18 167 0.7 115 22 178 0.5 
20. 1149 102 20 201 0.8 99 26 160 0.7 
 
LABORATORY INVESTIGATIONS (IP PATIENTS) 
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ANNEXURE-I 
 
PREPARATION OF TRIAL MEDICINE 
nts;sUF #uzk; 
(Reference: Gunapadam Mooligai Part-I Page No.843) 
 
Tamil 
Name 
Botanical Name 
(Family) 
Phytochemicals Action Therapeutic 
uses  
Vellarugu Enicostemma axillare 
Gentianaeceae 
Alkaloids, 
Carbohydrates,  
Glycosides, 
Flavonoids, 
Tannins, 
PhytoSterols. 
Proteins, Lignin, 
Saponins. 
Anti-ulcer, 
Anti-
spasmodic, 
Anti-
inflammatory, 
Anti 
microbial, 
Anti oxidant, 
Analgesic. 
 
Gunmam 
 
PURIFICATION OF DRUG: 
The ingredient of the herbal formulation was purified as below according to 
the proper procedure methods described in Siddha classical literature.  
Vellarugu-The whole plant was cleaned, washed in water & dried. 
 
 METHOD OF PREPARATION: 
Then the whole plant was dried in the shade until complete evaporation of the 
moisture content. It was made fine powder and kept in an air tight container. Then the 
Chooranam was purified by steam boiling process according to the Siddha classical 
text. It was labelled as Vellarugu Chooranam (VC). 
 
DISPENSING: 
In Outpatient department, 8g of 2 packets (each packets contains – 4g) 
chooranam was given for two days to a patient.  
In Inpatient department 4g of a packet chooranam was given daily. 
  
nts;sUF: 
 
Rit :  ifg;G 
jd;ik :  ntg;gk; 
gphpT :  fhHg;G 
 
nghJf;Fzk;:  
 
Fd;kNkhL tha;T Fly;thjk; #iyapit 
nrd;kk;tpl; Nlhbr;rpijAq;fhz; td;Kiyaha; 
cs;SWfp ue;jpnrhwp nahl;ba rpuq;FkWk; 
nts;sUF jd;id tpUk;G. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nts;sUF r%yj;ij Kiwg;gb #uzk; nra;J ,UNtis nfhLj;J tu 
Fd;kk; jPUk;. 
 
ANNEXURE - II 
GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI - 2. 
Department of Pothu Maruthuvam 
A prospective open labelled non randomized phase II clinical trial to assess 
the therapeutic efficacy of the Siddha formulation Vellarugu chooranam for 
the treatment of Erigunmam (Peptic Ulcer Disease) 
CLINICAL ASSESSMENT DURING AND AFTER TRIAL 
Clinical Assessment Score:  
1. Burning sensation in upper abdomen (Siru vayittril erichal) 
2. Nausea (Kudal kumattal) 
3. Water brash (Vayil neer ooral) 
4. Headache (Thalaivali) 
5. Flatulence (Vayiruppal, Eraichal)  
6. Dizziness (Kirukiruppu) 
7. Excessive sweating (Mayirkalil viyarvai peruguthal) 
8. Loss of body weight (Udal ilaithal) 
9. Loss of appetite (Pasiyinmai) 
10. Neuritic pain (Udal erichal)  
11. Cough (Irumal) 
Clinical Assessment Score    =    Number of present symptoms   ×  100 
             Total number of symptoms 
Grade 0 = 0 – 5 Grade I = 6 – 10 Grade II – 11 - 40 Grade III 41 – 70 Grade IV Above ≤ 70 
Visit 1/ date : ____________________________Score __________Grade _______  
Visit 2/ date : ____________________________Score __________Grade _______  
Visit 3/ date : ____________________________Score __________Grade _______  
Visit 4/ date : ____________________________Score __________Grade _______  
Visit 5/ date : ____________________________Score __________Grade _______  
 
_____________________               ______________________  
Signature of the Guide      Signature of the Investigator 
                                             __________________                 
Signature of the HOD 














